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ABSTRACT
Since their inception in the late 1970’s magnetic nanomaterials have sparked
heavy research into their use in the biomedical field. Their unique magnetic properties
allow the magnetic particles to be the base for a large array of expiremental medical
techniques, from treatments of disease, diagnostic tests, imaging aids, and more. In this
manuscript, each stage starting from novel particle synthesis, functionalization with
bioactive molecules, and innovative application is explored, specifically using the
techniques magnetically mediated energy delivery, magnetophoresis, magnetic resonance
imaging.
The reproducible synthesis of nanomaterials is necessary if any further
engineering application is going to be done. Using a novel extended LaMer approach
where a precursor solution is consistently added to a reaction vessel allows for the linear
volume growth of nanoparticles. This technique was originally used for the synthesis of
magnetite (a simple ferrite) to control the volume of the particle indefinitely. Transferring
it to a nonstoichiometric cobalt ferrite, it is shown that a linear volume growth is achieved
up to 20nm.
Secondary functionality of the magnetic particles has really opened up the
application to sensing, selective treatment, and functional imaging. Surface modification
with a bacterial strain discriminatory glycan allows for strain selective treatment of
bacterial infection. Heparin functional particles show high pharmacokinetic activity for
the treatment of neointimal hyperplasia due to high surface area to volume ratios.
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Gadolinium coated particles have distance dependent effects on the MRI relaxation rate
of water, which may prove useful in functional imaging.
Each of these complexes shows promise as a new way to treat or image malady.
Although a small part in the large picture in developing a new generation of medicine,
this research lays the foundation for each of these possible treatments. Be it the
eradication of bacterial infection or the non-toxic prevention of restenosis, novel
multifunctional nanomaterials such as the ones discussed in this manuscript, will be
heavily relied on in the future of medicine.
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CHAPTER ONE
Introduction to Magnetic Nanomaterials in Medicine
Magnetic nanomaterials have grown ubiquitous in the biomedical field for their
wide variety of applications ranging from basic transfection promoters to targeted disease
treatment and theragnostics. This large body of applications is only possible due to the
unique properties of nanoscale magnetic particles which is important to understand when
discussing their use. Although there is a large number of magnetic materials where these
properties manifest at the nanoscale, one particular class, ferrites, are heavily used in the
medical field due to their low toxicity, desirable magnetic properties at body temperature
and high versatility.1
Within ferrite materials the most commonly studied and implemented in material
is magnetite (Fe3O4) which has a relatively high magnetic saturation, with bulk being 90
emu/g and particle saturation magnetization between 30-90 emu/g, and is one of the
simple ferrites as it contains only iron in both the 2+ and 3+ oxidation state. 2 For the sake
of simplicity, this introduction will focus on magnetite as the primary example of
magnetic nanoparticles when looking at important magnetic properties and their
manifestation in biomedical applications.

1

Figure1. Medical applications relying on the magnetic properties of
nanoparticles. i) In MRI, magnetic nanoparticles affect the magnetic relaxation rates of
hydrogen atoms in each tissue type, resulting in a contrast in MRI. ii) Applying an
alternating magnetic field to magnetic nanoparticles can induce heat generation. The
resulting temperature increase in tissue can induce tumor cell death and/or enable
temperature‐controlled drug release. iii) Drug‐loaded magnetic nanoparticles
accumulated at a target site by a magnetic attraction force. iv) Magnetic removal of
pathogens and/or circulating tumor cells as a potential new therapy that differs from
drug administration and surgical intervention. Hyek Jin Kwon, Kwangsoo Shin, Min Soh,
Hogeun Chang, Jonghoon Kim, Jisoo Lee, Giho Ko, Byung Hyo Kim, Taeghwan Hyeon:
Large-Scale Synthesis and Medical Applications of Uniform-Sized Metal Oxide
Nanoparticles. Advanced Materials. 2018, Online early view, Copyright Wiley-VCH
Verlag GmbH & Co. KGaA. Reproduced with permission.

2

The magnetics of the particles depend on multiple different variables including
the magnetocrystalline anisotropy and the magnetic moment. Each of these can be
controlled via particle synthesis, but it is important to differentiate the method of control.
Magnetocrystalline anisotropy defines the energy requirements to magnetize along
different crystal lattice axes. This means that there exists an “easy axes” where the
moment is preferentially aligned and at its lowest energy state, as well as a “hard axes”
which takes a large amount of energy to magnetize along. This anisotropy magnitude and
direction are both inherent to the material in question meaning that each chemical
makeup of a material has a unique constant that defines this. To change this value, it is
necessary to change the actual chemical formula and crystalline structure of the material.
It is true that this magnetocrystalline anisotropy value does not describe the whole
anisotropy contribution of the particle system as it does not include surface, defect, or
shape effects. It is arguably the largest contributor to this total anisotropy value and
therefore an important variable to consider.
The magnetic moment of the particles is representative of the magnetic strength
and orientation of the field produced for the particles. The moment’s magnitude is limited
by the saturation magnetization of the material. This is an important value as it partially
describes the forces and behavior that particle may respond to inside of an applied field
and field gradient. This total moment is highly dependent on particle radius and the
inherent magnetism exhibited whether it is above or below the blocking temperature of
the particle. Particles on the nanometer scale may exhibit superparamagnetic behavior
above their blocking temperature which is defined where τ m = τ0 in equation 1, where TB

3

is the temperature, K the anisotropy energy density, V is the particle volume, kB is
Boltzmann constant, τm is the measurement time, and τ0 is attempt period.

Eq. 1 𝑇 =

(

)

When the Néel relaxation time (attempt period) is much less than the
measurement time, the moment is random and so net magnetization is zero, this is known
as the super paramagnetic regime. As the Néel relaxation time approaches the
measurement time, the moment cannot relax so a measurable magnetization is observed.
The temperature at which this switch occurs is called the blocking temperature.
Essentially the net moment of a superparamagnetic particle solution is zero without a
field. This is due to adequate thermal energy overcoming any dipole and anisotropic
energy limits allowing the single moments to orient randomly. In the presence of an
external field however, the particle moment will align parallel with the field.
Superparamagnetism is also associated with a zero magnitude magnetic hysteresis when
measured with relatively slow measurement times (< kHz). Thermal fluctuation and
magnetic relaxation to the easy axis via internal electronic Néel relaxation or viscous
physical Brownian relaxation is adequately fast that a zero hysteresis is measured.
Typical DC magnetization vs. field loops have a slow sample rate and therefore show this
curve which has become standard for showing superparamagnetic behavior.

4

Figure 2. A) Example magnetization vs. field loop showing superparamagnetic
behavior when measured in a DC magnetometer. Note the lack of hysteresis. B) Zero
field cooled-field cooled loop showing the blocking temperature of the particles at
approximately 250K.

The distinct magnetic properties of the particles allow for their use in multiple
different biomedical applications. This includes but is not limited to magnetically
mediated energy delivery (MagMED), magnetophoretic targeting, magnetic resonance
imaging contrast, biosensing, magnetic particle imaging, and many others. Specifically,
MagMED, magnetophoretic targeting, and MRI contrast are of particular interest and will
be discussed in depth.

Magnetically Mediated Energy Delivery
Magnetically mediated energy delivery (MagMED), formally known as magnetic
field hyperthermia, has been a heavily researched area in the magnetic community for
many years.3-7 The concept behind this technology is that an alternating magnetic field is
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applied to particles in and around a specific cell population. The particles convert the
energy of the magnetic field and deliver it locally to the cells. 8, 9 It was thought that the
energy transfer potentially causes a local elevation in temperature respective to the
magnetic materials, which can exceed the feasible temperature limit of the target tissue
causing cell death.10-14 However, the complex nature of this energy transfer is poorly
understood, as several groups have demonstrated cell death with no bulk heating. 15-20
Because of the misnomer, MagMED is now the preferred term of this group and others
for what was previously known as magnetic field hyperthermia.
The idea of locally induced energy delivery goes back to 1957 with the direct
injection of maghemite (𝛾-Fe2O4) into tumorous lymph nodes followed by treatment with
an alternating magnetic field.21 Since then, the idea of local heating has attracted both
research and clinical interest for its ease of treatment, efficacy, and low degree of
invasiveness.22 Traditionally, this work has been centered on iron oxides including the
most commonly studied phases, maghemite (𝛾-Fe2O3) and magnetite (Fe3O4.). Much of
this research is directed towards the synthesis, characterization, and application of iron
oxides. Despite significant research activity, there are limited commercial and clinical
applications of these materials to date. One reason for this is the limited properties of Feferrite materials.
More recently, to improve upon the material properties of iron oxides, researchers
have begun to consider substituted and doped ferrites. These complex materials show a
wide range of magnetic properties, including tunable magnetic saturation,
magnetocrystalline anisotropy, and blocking temperature.23 Coupled with recent
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advancements in synthesis, and increasing control over both size and morphology of
nanoscale colloids, these new materials have been shown to exhibit properties that are on
the cusp of being clinically relevant for MagMED.

Figure 3. Representative figure showing the calorimetry setup for SAR values. A)
Optical thermocouple submerged in solution to measure heating. B) Typical time vs
temperature graph, note the initial slope is used for SAR calculations. C) Hollow
induction coil with water coolant. D) Water jacketed sample holder for equilibration of
sample temperature before measurement. E) Sample enclosure and cap are necessary for
sample manipulation and to reduce evaporation. F) Known volume of sample used (in
this case 0.5ml of toluene). G) Illustration of moment switching with the AC field causing
energy transfer from the particles.

MagMED treatments primarily rely on the optimization of one parameter, the
specific absorption rate (SAR), which describes the efficiency of energy conversion at a
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given field and frequency.24 The SAR parameter is normally measured by inserting a
known concentration of particles into a coil and observing the change in temperature as a
function of time of the colloid or solid sample. This value can then be used to calculate
SAR for the material in question as is seen in equation 2.25 SAR is reported as the power
per unit mass of sample, Cp is the specific heat capacity of the colloid, ∆T/∆t is the
measured slope of the time dependent heating curve, and 𝜑 is the mass fraction of the
material in gmaterial/gsolution.

Eq. 2 𝑆𝐴𝑅 =

∆
∆

Although this is the most common way the SAR values are calculated, this
method does not account for both the field and frequency specific contributions of the
energy transfer. Some groups have argued to normalize this value by dividing by the
frequency and the field squared.26 However, as discussed below, the field and frequency
dependency makes this an inherently flawed normalization. Nonetheless, the energy
produced for each cycle can be described by the hysteresis loop area of the particles in
the AC field as:

Eq. 3 𝐴 = ∫

𝜇 𝑀(𝐻)𝑑𝐻

where A is the energy released, 𝑀(𝐻) is the field dependent magnetization and 𝜇 (Hmax)
is the field amplitude. It should be noted that this loop is often different to one measured
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using traditional magnetometry techniques that have much longer measurement times.
Put a different way, hysteresis loops measured using traditional magnetometry, i.e.
vibrating sample magnetometry with a superconducting quantum interference device
(SQUID) detector, do not correctly represent behavior at the field and frequencies of
MagMED.
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Figure 4. Evolution of the hysteresis loop as a function of field frequency and
characteristic particle relaxation time showing there exists optimal conditions for each
particle system to get the largest energy transfer. Too low a frequency and the particles
behave as paramagnets, too high a frequency and the particles are never directionally
magnetized. Figure was taken from J. Carrey, B. Mehdaoui, M. Respaud, Simple models
for dynamic hysteresis loop calculations of magnetic single-domain nanoparticles:
Application to magnetic hyperthermia optimization Journal of Applied Physics 2011,
109, 083921. Figure was reprinted with permissions from AIP Publishing.

Nonetheless, the time dependent energy release rate can then be multiplied by the
frequency (𝑓) to give the SAR value (equation 3).24
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Eq. 4 𝑆𝐴𝑅 = 𝐴𝑓

The critical value in equation 4 is the energy/heat generation per cycle, and it is
this value that materials chemists are able to greatly influence through tuning physicalchemical parameters relating to the energy transfer mechanism. This mechanism results
from hysteretic loss which has been described for single domain magnetic nanoparticles
above the ferromagnetic transition point.24, 27, 28 At smaller volumes, using the linear
response theory this hysteretic loss mechanism occurs under the superparamagnetic
threshold value where particle sizes are much smaller than their ferromagnetic
counterparts. In this case, the combined Néel and Brownian relaxation time as a function
of frequency contributes to the energy loss. By matching the frequency with the specific
loss peak it is possible to optimize small particles under their ferromagnetic threshold.
This size dependent response emphasizes the importance of the magnetic volume on the
resulting properties. More so, different particle sizes strongly vary the properties of
biodistribution, circulation time, and clearance.29, 30 This superparamagneticferromagnetic transition volume is material specific, thus it may be possible to create
particles that both exhibit hysteretic loss and have the distribution properties of their
smaller counterparts.
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Nanoparticles for Magnetophoretic Targeting
Magnetophoretic mobility and targeting is a technique that used the high
saturation magnetization of the particles to magnetically attract the particles to a specified
area via a large induce field gradient. This method of targeting is attractive for in vivo use
because the particles will only respond to an externally applied field which can be
specific to an anatomical region or induced in magnetizable implants. 31-35 Particles once
outside of the targeted field region will revert back to a random state and maintain
stability until either they are cleared biologically or circulated and see the field again.
This is important as it makes follow up treatments minimally invasive and allows for
non-specific biological moieties to be selectively targeted, increasing accumulation at the
target site and reducing the possibility of systemic side effects that would occur in typical
administration.36
The efficacy of this technique is highly dependent on many factors including the
particle magnetization, field gradient, and surface chemistry of the stabilizing ligand. The
gradient and moment of the particle must be sufficient enough that it overcomes both the
stabilization of the particle in solution as well as viscosity effects from the ligand
interaction within the solvent.37-40 It is also important to note that most applications in
vivo require the targeting to happen in some vascularized tissue. This is not a static
environment and so there exists a flow rate which gives the particles a small time window
to be captured. Again this may be expanded through either multiple administrations or
bioinert surface chemistry which impart a “stealth” property by manipulating the protein
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corona, increasing their biological halflife essentially allowing them multiple passes
through the target site.41
Currently the use of the magnetophoretic properties is gaining interest in
externally directed drug delivery and cell transport. This includes much research into
using magnetite decorated endothelial cells to reduce the probability of in-stent
restenosis. This treatment is surprisingly effective considering the forces needed to
significantly move cellular organisms. The magnetic force created is from an implantable
stent is a function of the particle magnetic moment (𝑚⃗), the field gradient due to the stent
struts (∇𝐵⃗ ), and the externally applied homogeneous magnetic field (𝐵⃗ ).

Eqn. 3 𝐹⃗

= 𝑚⃗ ∙ ∇𝐵⃗ 𝐵⃗

The importance of both the magnetic moment of the particle, and the field gradient
created from the magnetic stent struts are seen in equation 3. This illustrates the need for
high magnetic saturation particles as well as a highly magnetizable stent. Another option
that may be used to increase the gradient would be to replace the homogeneous field with
a large field gradient. Issues in uneven targeting may occur as the particles will be forced
down the external gradient.

Nanoparticles in MRI
The use of magnetic nanoparticles as magnetic resonance imaging (MRI) contrast
agents has been of particular importance and is one of the most heavily researched
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properties, with agents going so far as being approved for medical use by the United
Stated Food and Drug Administration.42 With the implementation of MRI in the 1970’s
and 80’s, came an influx of contrast related research. Ferrite particles were seen to impart
large changes in T2 relaxation rates, and started being evaluated as diagnostic tools as
early as 1986.43 Since their inception, contrast agents have been crucial in the diagnostic
field as they allow clinicians to differentiate between tissues or fluids in the body that
may have similar relaxation signals. These agents are typically split into two different
categories, T1 and T2 agents.
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Figure 5. Illustration of T1 and T2 contrast effects. T1 agents brighten as
concentration increases, where T2 agents darken with concentration.

This refers to the mechanism of relaxation that they predominately change. In
magnetic resonance, each unique proton in the applied field is aligned either parallel or
antiparallel to the applied field. Due to Zeeman splitting there is a degeneracy, meaning
that there are a slightly disproportionate number of spins aligned parallel to the field.
Each of these spins processes around the field vector at a rate defined by the field
magnitude and chemical environment of the proton.44 This procession is named the
Larmor frequency. For T2 in a thermally equilibrated system there is no phase coherence
between moments, so no signal can be measured. When a specific radio frequency pulse
is applied to the system, the magnetization vector of the protons is shifted into the X, Y
plane from the initial magnetization along the Z axis.
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Figure 6. T2 relaxation mechanism showing net moment along z axis, phasing 90
degree pulse and dephasing of the spins. X axis magnetization (signal) is shown below
spin diagrams illustrating why T2 is inherently negative contrast or signal loss.

The T2 relaxation is defined by the dephasing time of the RF phased magnetic
moments which is constituted by a loss in signal magnitude in the X-Y plane. This
dephasing is defined by equations 6 and 7 below where 𝑀 and 𝑀 are magnetization in
the respective planes, 𝑀 is the initial magnetization, t is the time, T2 is the relaxation and
ω is the frequency of procession. Typically the T2 relaxation is defined as the time when
the signal magnitude is equal to 1/e.44

Eq. 6 𝑀 (𝑡) = 𝑀 𝑒

𝑆𝑖𝑛(𝜔𝑡)

Eq. 7 𝑀 (𝑡) = 𝑀 𝑒

𝐶𝑜𝑠(𝜔𝑡)
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Because T2 based contrast agents lower the time it takes for the signals to
dephase, it is known as negative contrast enhancement essentially making the image
taken from the MRI appear darker when compared to a control image. Magnetic
nanoparticles are well defined as T2 contrast agents as they induce large changes in the
T2 relaxation mechanism. Because of the large local field generated by the particles,
large differences in the field gradients are felt by nearby protons changing each unique
procession frequency. This in turn accelerates dephasing as the field defining the Larmor
frequency (𝜔 ) of each proton is now a function of summation of the applied field (𝐵 )
and the local field from the particle (𝐵 ) as seen in equation 8.

Eq. 8 𝐵 + 𝐵 = 𝐵

∝𝜔

Although T2 is not preferred by most clinicians, as it is negative contrast, there
are very large changes in the hyperintensity signal produced by the magnetic particles.
Typical changes in T2 signals generated by magnetite nanoparticle based contrast agents
are an order of magnitude greater than their gadolinium counterparts. 45 The large T2
effect means that the T2 signal will overwhelm any T1 weighted signal from the
particles, so positive contrast T1 imaging is difficult. Although not typically used in
positive contrast T1 weighted scans, the large T2 effect allows for magnetite
nanoparticles to find niche uses in diagnostics for mainly hepatic ailments where particles
gather quickly at the target site.46 Although promising, there have been some issues with
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the particles for T2 contrast agents as they have been seen to cause adverse effects in
some patients including cardiovascular distress and lower back pain. 47 This may be due to
the propensity of the particles to form long mesoscale chains over time in a magnetic
field which was shown by Saville et al.48 Any magnetic interactions between particles are
essential to suppress as aggregation in vivo may cause changes in the behavior of the
material. This again alludes to the surface chemistry playing a large role in the stability
and even magnetics of the particles, as a larger more steric surface chemistry may delay
or hinder chaining from occurring on the timescale of measurement.
Although magnetic nanoparticles are not typically used as T1 contrast agents, it is
important to distinguish the difference in the relaxation mechanism from T2 as there is
research into possibly using them particles as dual contrast agents. The T1 phenomena is
the relaxation back to thermal equilibrium in the z direction after a “demagnetizing”
pulse is applied. Because you are looking at the regain of signal it is inherently a positive
contrast mechanism, which shows up as bright spots on typical MRI scans.
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Figure 7. T1 relaxation mechanism showing initial signal from net moment along z axis,
90 degree pulse and Relaxation back to thermal equilibrium. Z axis magnetization
(signal) is shown below spin diagrams illustrating why T1 is inherently positive contrast
or regain in signal.

This is much easier to distinguish than its T2 counterpart in an image readout. Unlike
typical T1 contrast agents, which are made up of chelated paramagnetic metal ions like
gadolinium, the ratio of T2 to T1 of a magnetic nanoparticle is so high that the T2 signal
swamps any T1 weighted measurement which does not allow particles to be used at T1
contrast agents on their own. The idea to use dual weighted T1/T2 imaging is ideal as it
can eliminate artifacts unique to each of the different imaging modalities using an AND
gate which compares the images to see if contrast is present in both images. 49 This
method of imaging relies on the fact that the T2 signal from the particles will not
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influence the T1 weighted imaging. Changes in the particle size and surface
functionalization can affect the particle specific relaxation rates. This can amount to
lowering the T2 and increasing the T1 so that dual mode imaging is viable.

Surface Chemistry
Just as important as the magnetic properties of the particle is the surface
chemistry, which imparts stability, functionality, and biocompatibility. Without a robust
chemistry, the particles are not suitable for use in vivo as they may lose potency, and
potentially pose a significant health risk. Many studies have looked at the toxicology of
nanomaterials in general and it is agreed upon that the surface chemistry, and access to
particle crystal faces plays a large part in determining the overall toxicity. 50 Not only is
the toxicity of magnetic nanomaterials highly dependent on the surface chemistry, the
magnetics are also affected.51 Because magnetite is relatively benign and is metabolized
into useful iron, toxicity and metal ion leaching or degradation in vivo is not nearly the
issue it is with other substituted metal ferrites e.g., CoFe 2O4, NiFe2O4, or MnFe2O4.52, 53
Although magnetite may not have inherently toxic metals, the system still may lose
potency if leaching occurs, and it serves as a model system for other mixed ferrite
systems, as good binding moieties for magnetite carryover to the other ferrites.
The method of particle synthesis changes the method and ease of attaching
biologically stable ligands. “Nude” particles synthesized via coprecipitation are charge
stabilized so surface modification is relatively easy as there are no competing ligands to
bind to the surface or replace. Unfortunately, coprecipitation, although easy, gives
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particles that are typically polydispersed and irregular in morphology. For many
applications it is important to control the size and shape to a high degree. This is much
easier done via thermal decomposition of organometallic precursors. The tradeoff for this
control is that they are typically sterically stabilized via hydrophobic ligands. These are
more difficult to replace as they are already bound to the magnetic particles and, even
after purification, present in heavy excess. The common method for modification to a
biocompatible material involves ligand exchange which uses an energy source,
commonly sonication, to increase the exchange of ligands. By introducing a competing
ligand with higher binding affinity, overtime the particles should be preferentially coated
with the new ligand.
A large amount of time and effort has gone into identifying high affinity organic
moieties to bind to the surface of magnetic nanomaterials. Davis et al. have shown that
there are effectively two binding groups, catechol and phosphonate, which have the
highest affinity for ferrites and should be used for ligand binding or ligand exchange
procedures as seen in figure 8.54
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Figure 8. Chains of oleic acid remaining on the surface of the nanoparticles
before and after ligand exchange determined by LSC. The data for the PEG-coated
nanoparticles represent the amount of oleic acid remaining after dialysis. The lower the
chains of oleic acid the greater the extent of ligand exchange. Reprinted (adapted) with
permission from Quantitative Measurement of Ligand Exchange on Iron Oxides via
Radiolabeled Oleic Acid, Kathleen Davis, Bin Qi, Michael Witmer, Christopher L.
Kitchens, Brian A. Powell, and O. Thompson Mefford, Langmuir 2014 30 (36), 1091810925, DOI: 10.1021/la502204g. Copyright (2014) American Chemical Society.

These moieties are typical in literature and are commonly used as the anchoring site for
large macromolecules which further stabilize, and disperse the particle in aqueous media.
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Although the binding affinity of these groups is so high, it is not uncommon to see
difficulties in maintaining a stable colloid under biological conditions. This is due to the
relatively large amounts of both salts and proteins in typical human serum as well as
possible competing ligands in biological systems. One effective strategy to avoid possible
surface polymer detachment is to have multiple anchor points for each macro molecule.
Saville et al. have shown that by increasing the number of catechol binding groups from
one to three on the end of a stabilizing macromolecule, the particles maintain stability in
not just high salt content solutions of phosphate buffered saline but high protein solutions
of fetal bovine serum as well.55 This is due to the difficulty of detaching the ligands that
are bound in triplicate to the particles. The stability conferred by this multiple binding
scheme is of the utmost importance as destabilization of the particles, due to unwanted
ligand exchange and aggregation, does not occur and the particles can be suspended.
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Figure 9. Typical bifuctional PEG based ligand. A. Monoanchored PEG with a
catechol anchor and alkyne functionality for click chemistry after exchange. B.
Multianchored amine functional PEG ligand with poly acrylic acid acting as the
backbone to conjugate the binding catechol and PEG.

One of the most common macromolecule used in the biocompatibility and
stability process is poly(ethylene oxide) (PEO) also referred to as poly(ethylene glycol)
(PEG). PEG is a simple polyether that is bioinert and nontoxic when the molecular
weight is above a threshold value. Although water is not an ideal solvent, it solvates and
disperses relatively well. PEG is commonly used in the pharmaceutical industry to aid
delivery and increase circulation times of hydrophobic drugs, and is even approved for
use as a laxative as it solvates and retains water, but does not interact with electrolytes.
This same mechanism is what makes PEG an optimal coating for nanoparticles in general
as it interacts with the water but is relatively inert to ions and pH changes. 56 Other surface
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coatings have been explored including dextran, which is a polysaccharide that imparts
stability, and albumin, which is a biologically derived protein, but these coatings do not
have the low interaction potential that PEG does due to the large amount of functional
groups contained in the polymer.57
PEGs used to impart stability in particle systems are typically multifunctional,
meaning they have two different endgroups where they can be further modified.
Typically one end will be composed of the anchoring group (typically a catechol or
phosphonate derivative). This group binds to the particle attaching the PEG to the
surface. The other endgroup is typically tailored so it can be reacted with biomolecules
that give more functionality to the particles. This can be a targeting molecule such as an
antibody or glycan, a pharmaceutical, e.g. heparin, or other moieties that impart
secondary functionality or change the behavior of the particle e.g. Contrast agents,
clustering particles through crosslinking etc.58-61 This ability to conjugate any number of
other molecules to the surface, greatly enhances the prospective uses of the particles for
biomedical application. Another common modification is using PEG and PEG blockcopolymers to impart release conditions of a drug be it temperature, pH, or some other
outside stimulus. Typically the PEG block will be on the surface to impart the stability
where the stimuli reactive block will be the intermediary between the particle and the
PEG coating.62 These intermediary blocks can be made up of different polymers, and is
typically where the drug of choice is loaded.63
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Magnetic Particle Synthesis
In recent years a large amount of research has gone into developing highly
controllable synthesis methods for nanoscale colloids. This is especially true with magnetic
nanoparticles, as they have been one of the most sought after nanoscale materials. Because
of this, the various synthesis methods of metal ferrite nanoparticles have grown both
simpler and more reproducible. It is now possible through a variety of methods to obtain
monodispersed

nanoparticle

populations,

phase

pure

crystallites,

controllable

morphologies, and a range of sizes. This is important, as requirements for the optimization
of particle systems for use in MagMED, sensing, and many other applications are stringent,
and even slight deviations from these parameters can have a drastic effect the efficacy of
the particles.
Of the vast array of synthesis methods, a few are more commonly used and seem
to yield the best results for tuning particle parameters important for their use in the
biomedical field. The first and most recognizable is coprecipitation. In essence, the
synthesis uses a variety of metal salts containing both an Fe 3+ cation and a mixture of M2+
cations (M = Mn, Zn, Fe, Co, Ni, etc.) dissolved in an aqueous system.
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Figure

10.

Coprecipitation

synthesis

of

magnetic

nanoparticles,

with

representative image of particles produced. Although the reaction is simple, control over
morphology and size is minimal.

This can be done in the presence of a stabilizing surfactant that will eventually cover
and sterically or electrostatically stabilize the particles. However inclusion of surfactant is
not necessary as bare particles resulting from the reaction will have charged surface groups
granting them stability at defined pH conditions. Normally the precipitation of the
nanocrystals takes place after a base is added and instabilities in the system cause the
nanoscale crystallites to crash out of the solution creating an emulsion. These are then
separated from the supernatant by antisolvent precipitation or magnetic separation and
carefully washed to remove excess salts, surfactants, etc. It is imperative that the pH values
of the solution are carefully monitored, as coprecipitation particles are prone to
agglomeration. Variables contributing to the particle parameters include the specific anion
chosen, reaction temperature, stirring rate, pH value and the ionic strength of the solution. 64
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Coprecipitaion particles are widely used as their synthesis is relatively easy, and the
particles as synthesized are water suspendable. However, difficulties in controlling the
exact morphology, wide size distributions, and potential stability issues are drawbacks of
the coprecipitation synthesis method.64, 65
The second widely used method is thermal decomposition. This method of
synthesis allows for a high degree of control over particle size and dispersion. 64, 66 This is
important when considering techniques that require more stringent magnetic parameters
like MagMED, as it allows for more precise tuning of size and morphology both of which
contribute to the overall SAR of the material.24, 67 It has also been shown in literature that
various more complex materials such as doped ferrites and core shell particles are able to
be synthesized this way.66 This method of preparation uses an organometallic precursor for
the metal ion source.

Figure 11. Example thermal decomposition synthesis reaction for magnetic
nanoparticles. Oleic acid is the stabilizing ligand which is coating the particles. Although
more difficult, high control of particle size and morphology is achieved.
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The precursor is normally mixed in with both a high boiling point organic solvent
and an organic capping ligand (the most common being oleic acid). The reaction is run at
high temperatures for varying amounts of time causing the organometallic precursor to
decompose, yielding a solution of free metal ions. At a critical supersaturation point nuclei
crash out of solution and the particles go through a growth phase. This growth phase can
be controlled by constant introduction of the metal precursor, effectively regulating the
amount of free iron available for the particles. Cooley et al. demonstrate an “extended
LaMer” approach and show incredibly high degrees of size control with low size
dispersion.67, 68 When the reaction is cooled the resulting particles are homogeneous in size
and shape, but they are rendered insoluble in aqueous solutions due to the long chain fatty
acid stabilizing ligand.67
The non-polar surface coating of oleic acid is problematic when considering particle
use for MagMED, as the particles as synthesized are not biologically viable. Much work
has been done in looking at the post modification of oleic acid coated particles by
encapsulation or ligand exchange with biocompatible macromolecules such as
poly(ethylene glycol), bovine serum albumin, dextran, etc. to overcome the compatibility
issues.54 Another issue relating mainly to metal ferrites is in the variable decomposition
temperatures of different organometallic precursors.69 These differences play a large role
in determining the chemical makeup of the particles, and can be attributed to unexpected
morphologies obtained. Although initially perplexing, compositional dependence on
chosen precursor for thermal decomposition is promising and may be exploited in future
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work to obtain varying degrees of substitution while retaining the advantages in particle
size control and a low degree of dispersion.
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CHAPTER TWO
SYNTHESIS OF SUBSTITUTED METAL FERRITE NANOPARTICLES
Introduction
Addressing the challenges of MagMED from a materials perspective is done
primarily the initial particle synthesis. This is where the anisotropy, and the particle
volume can be explored and optimized. In this study we look at multiple transition metal
substituted ferrites and their utility as a MagMED platform. Using a one pot synthesis,
chosen compositions were screened, using specific absorption rate as a measurement of
efficacy in energy transfer. Energy-dispersive X-ray mapping was used to investigate the
elemental composition and morphology.
From the initial one pot synthesis and characterization of the doped metal ferrites,
the doped cobalt ferrite had the largest SAR value, as well as homogenious loading
throughout the lattice of the substituted cobalt. This along with cobalt ferrites already high
anisotropy led us to focus on the cobalt system. Traditionally, research in MagMED has
been centered on the most commonly studied iron oxide phases, maghemite (𝛾-Fe2O3) and
magnetite (Fe3O4). Despite significant research activity, there are currently limited
commercial and clinical applications of these materials. Recently, to improve upon the
material properties of iron oxides, researchers have begun to consider substituted and
doped ferrites1-5. These materials show a wide range of magnetic properties, including,
tunable magnetic saturation, magnetocrystalline anisotropy, and blocking temperature. 6
Coupled with recent advancements in synthesis, and increasing control over both size and
morphology of nanoscale colloids, these new materials have been shown to exhibit
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properties that are greatly improved from those of Fe-ferrites. One of these select materials
is cobalt ferrite (CoFe2O4), which has a much greater effective anisotropy due to the
replacement of the Fe2+ with the highly anisotropic Co2+ ions.7,

8

By maximizing the

effective anisotropy through Co doping, specifically between cobalt levels between 0.4 and
1 in CoxFe3-xO4, as well as identifying the optimal volume for energy release using a novel
extended LaMer synthesis, the optimization of cobalt ferrite based materials for application
in MagMED is possible.9, 10 Herein, we describe a potential synthetic method to produce
these materials in a size controllable manor, and the resulting properties of the particles
relating to MagMED.

Experimental
One-Pot Thermal Decomposition Synthesis
Initial investigation of doping effects was done using a one-pot synthesis of cobalt
ferrite particles. Stoichiometric amounts of both iron (III) acetylacetonate and cobalt (II)
acetylacetonate were combined in a 100 ml 3-neck round bottom flask, for a total amount
of 3.04 mmols of organometallic precursor. Oleic acid (15 ml) was then added, serving
both as the solvent and primary ligand for particle stability. The vial containing the
solution was placed into a metal bath at 200 °C, nitrogen purged, and then quickly
ramped to 350 °C, to avoid heating rate variance. The solution was left to sit, under
nitrogen and stirring with an overhead stirrer, for 3 hours. Samples were precipitated with
an ethanol: acetone mixture (3:1) (3x) and resuspended in toluene. The samples were run
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through an organic based gel permeation chromatography (GPC) column to purify off
excess oleic acid and unreacted organometallic precursor11.

Metal Oleate Precursor Synthesis
Metal oleates were synthesized by combining 9.3 mmol of metal acetylacetonate
and 15 ml of oleic acid in a 100 ml 3-neck round bottom flask. The reaction was initially
purged and performed under constant (<50 ml/min) nitrogen flow. After adequate
purging of the flask, it was heated to 320 °C for 20 minutes and then quenched by
removing the heating source, yielding a dark, oily liquid that did not respond to an
external magnet. Fourier-transform infrared spectroscopy was performed to confirm the
presence of the oleate complex with the minimization of the free acid peak at 1710 cm -1
and the appearance of the carboxylate anion with peaks at 1578 cm -1 and 1440 cm-1
shown in figure 1.

Figure 1. FT-IR of one-pot synthesized metal oleate precursors for extended LaMer.
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Drip Thermal Decomposition Synthesis
The metal oleate precursors were diluted to 0.22 M in octadecene to help with
injection into the reaction flask. Diluted precursors were combined in specific
predetermined molar ratios and vortexed to ensure homogeneity. The precursor mixture
was loaded into a 10 ml syringe attached to a penetration needle, and affixed to a syringe
pump. The 3-neck flask was loaded with 2.5 g of docosane and 2.5 ml of oleic acid and
heated to 350 °C under inert (nitrogen) atmosphere. When the solution temperature was
stable, the precursor solution was added at a rate of 3 ml/hr. Aliquots were started 20
minutes after the first addition of the precursor solution, and were taken every 5 minutes
for 90 minutes.

Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy
Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy
was done using a Thermo-Nicolet Magna 550 FTIR spectrometer. 16 Scans were done
for both the sample and the background. Samples were prepped by dropping a small
amount of the oleate sample onto a diamond crystal. Crystal contact was assumed to be
good due to the liquid nature of the sample.

Transmission Electron Microscopy
Bright field transmission electron microscopy was run on a Hitachi H7600 with a
variable spot size. Image analysis was done using Image J (NIH, open-source) on a
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minimum of 300 particles. High Angle Annular Dark Field Scanning Transmission
Electron Microscopy (HAADF-STEM) imaging and energy-dispersive X-ray element
mapping were carried out using a FEI Titan G2 80-200 TEM/STEM with ChemiSTEM
Technology operating at 200 kV. The element maps were obtained by energy dispersive
X-ray spectroscopy using the Super-X detector on the Titan with a probe size ~1 nm and
a probe current of ~0.9 nA.

AC Magnetometry
Volume AC magnetometry was run on an Imego Dynomag. 200 μl samples of
particles suspended in toluene were pipetted into a 1ml borosilicate glass vial. Peak
frequency was extrapolated from a best fit imaginary susceptibility curve.

AC Calorimetry
Specific absorption rate (SAR) measurements on particles were done using a field
of 38 kAm-1 at a frequency of 206 kHz. A sample containing 500 µl of purified particles
in toluene were transferred into a 1ml glass vial. The vial was inserted into the water
jacket contained within the coil and an optical temperature probe submerged into the
toluene solution. Toluene was used to minimize evaporation between runs. The water
jacket temperature was set to 37 °C. Once the sample temperature was stable, the power
source was turned on and run for 120 s. The rise in temperature was recorded as a
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function of time and the initial slope based on the first 40 seconds of heating was used in
calculating the specific absorption rate.

Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES)
ICP-OES was run using a Perkin Elmer Optima 3100 ICP-OES running WinLab32
version 3.1 analysis software. Particle samples were digested initially with 30% hydrogen
peroxide solution (Sigma-Aldrich) to remove organic. The peroxides were boiled off and
the remaining inorganic was digested with <70% nitric acid (ARISTAR PLUS, VWR).
The nitric acid was boiled off and the resulting nitrate salts were dissolved in a known mass
of 2% nitric acid solution and run against standard solutions.

Thermal Gravimetric Analysis
Thermogravimetric analysis (TGA) was used to investigate decomposition
temperatures of metal acetylacetonates. 5 to 10 mg of each sample was placed in a TGA
pan, which was analyzed using a TA Instruments 2950 TGA. The samples were heated
at 20 °C/minute under nitrogen purge to 110 °C, held at 110 °C for 30 minutes, then
heated at 15 °C/minute to either 500 °C or 800 °C.

Small-angle X-ray Scattering
Small-angle X-ray scattering (SAXS) experiments were conducted using a SAXS
LAB Ganesha at the South Carolina SAXS Collaborative at the University of South
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Carolina. A Xenocs GeniX3D microfocus source was used with a copper target to
generate a monochromatic beam with a 0.154 nm wavelength. The instrument was
calibrated using silicon powder (NIST 640e). Scattering data were processed from the
scattering vector q=4πλ−1 sinθ where λ is the X-ray wavelength and 2θ is the total
scattering angle. A 300K Pilatus detector (Dectris) was used to collect the twodimensional (2D) scattering patterns. SAXS GUI software was used for radial integration
of the acquired 2D patterns to reduce the data to 1D profiles. Sample solutions were
prepared by diluting the crude reaction product to <5 vol% in hexane to avoid structure
factor contributions to the scattering curve.
Samples were passed through a 200 μm syringe filter just prior to measurement in
a sealed glass capillary. A blank sample consisting of a capillary with only hexanes was
measured under the same conditions for background subtraction using SAXS GUI. All
samples were acquired for 15 minutes at room temperature with an incident X-ray flux of
∼21.4 M photons per second.

Small Angle X-ray Fitting
Nanoparticle dimension distributions were determined by fitting each SAXS data
as a Gaussian number distribution of hard spheres. Custom MATLAB R2014a programs
were used for the analysis. Here, the scattering intensity, I(q), for a single sphere of
radius R is
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Eq. 1

𝐼 (𝑞 ) = 𝜌 𝑣

(

)
(

)

where 𝜌 is the electron density contrast, and 𝑣 is the volume of the sphere, respectively.
The total scattering curve was calculated as a sum across a Gaussian distribution, taking
into account both the scattering strength and the relative abundance of each sphere radius
sampled. The fitting was performed by minimizing the residuals on a log(Iq 4) vs q basis.
The data were well fit by modeling form factors alone.

Results and Discussion
With the knowledge that composition could be used as a tool to alter the resulting
magnetic properties for application in MagMED, a series of substituted metal ferrites were
synthesized and systematically characterized to investigate their properties in relation to
MagMED. Particles were synthesized using a one pot thermal decomposition method
outlined in the experimental section. Characterization techniques applied were energy
dispersive X-ray spectroscopy (EDX), bright field transmission electron microscopy
(TEM), AC calorimetry, and inductively coupled plasma optical emission spectroscopy
(ICP-OES). SAR measurements on particles synthesized for this paper were done using a
field of 20 kAm-1 at a frequency of 206 kHz.
Bright field imaging (figure 2) shows slight variation of size within samples
containing the same dopant. This variation within a sample set is much smaller than the
variation between samples with different dopant materials. This is to be expected as both
lattice constants and kinetic growth are highly variable and depend on the chosen dopant.

48

Figure 2. Bright field TEM of substituted metal ferrites synthesized by one pot thermal
decomposition of metal acetylacetonate precursors at 350°C.
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It is important to note that size control for each of the varying dopants must be
independently developed as the kinetics and thermodynamics at play during the reaction
vary greatly depending on the dopant metal chosen. Because nanoparticle volume plays a
large role in defining optimal parameters for energy transfer efficiency, these differences
in size do not allow for highly accurate comparison of for example nickel ferrite and cobalt
ferrite. One can instead come to a set of broad conclusions evaluating how size and dopant
loading may affect the SAR values of given materials.
Complex morphologies in particles with differing phase as well as chemical
makeup in mixed ferrite systems are also possible, and seem to depend on the precursors
chosen for the synthesis. This difference in morphology is illustrated in figure 3, where
different metal acetylacetonates were chosen as the organometallic precursors for the
thermal decomposition reactions.
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Figure 3. EDS maps of particles made using different metal acetyleacetonates. Fe is always
in blue. A) Fe Zn, B) Fe Co, C) Fe Mn, D) Fe Ni

Because metal ferrites were the target of investigation, the iron precursor was typically
included in higher amounts than the metal dopant. Varying core shell morphologies may
correspond to largely dissimilar decomposition temperatures between precursors. Cobalt
(II) acetylacetonate has a similar decomposition temperature to the iron (III)
acetylacetonate, and it shows good incorporation throughout the lattice and relatively
accurate stoichiometry corresponding with the expected dopant concentration. Manganese
(II) acetylacetonate however has a much different decomposition temperature, and core
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shell/Janus effects are observed where local manganese loading is extremely high
compared to the particle shell. Stoichiometry is also highly variable corresponding with the
large differences in the decomposition. Thermal decomposition reactions are even further
complicated as an intermediate organometallic compound is formed from the free metal
ions, this is normally an oleate complex. The morphological effect due to precursor
decomposition is highly important when looking at particle optimization for MagMED, as
core shell or highly local loading will most definitely influence the materials’ properties
including anisotropy and magnetic saturation. Decomposition differences in this secondary
in-situ formed precursor are still under investigation. The variability in stoichiometry and
dissimilarity in precursor decomposition temperature can also affect concentration
measurements of MagMED contributing metal ions and skew SAR results.
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Table 1. Intended and actual particle composition as measured by EDX elemental mapping
Intended
Sample

CoxFe3-xO4

MnxFe3-xO4

ZnxFe3-xO4

NixFe3-xO4

EDX Actual

ICP Actual

SAR (W/gmetal)
--

Fe

M

O

Fe

M

O

Fe

M

2.75

0.25

4.00

2.5±0.16

0.18±0.018

4.2±.18

2.85

0.15

31.38

2.50

0.50

4.00

2.6±0.16

0.45±0.040

3.9±0.18

2.53

0.47

136.6

2.37

0.63

4.00

2.5±0.25

0.55±0.093

3.9±0.24

2.45

0.55

53.38

2.25

0.75

4.00

2.3±0.20

0.63±0.19

4.0±0.10

2.46

0.54

734.4

2.125

0.875

4.00

2.2±0.49

0.79±0.50

3.9±0.28

2.34

0.66

--

2.00

1.00

4.00

2.1±0.21

0.84±0.15

3.9±0.23

2.09

0.91

77.63

2.75

0.25

4.00

2.8±0.21

0.19±0.038

3.9±0.23

2.8

0.2

679.2

2.50

0.50

4.00

-

-

-

2.61

0.39

261.3

2.25

0.75

4.00

2.4±0.11

0.56±0.042

4.0±0.14

2.4

0.6

134.3

2.00

1.00

4.00

1.7±0.40

0.99±0.50

4.3±0.23

-

-

--

2.75

0.25

4.00

3.0±0.12

0.15±0.030

3.7±0.11

2.74

0.26

346.4

2.50

0.50

4.00

-

-

-

2.45

0.55

295.3

2.25

0.75

4.00

2.9±0.29

0.17±0.052

3.9±0.27

2.28

0.72

323.0

2.00

1.00

4.00

-

-

-

-

-

--

2.75

0.25

4.00

2.4±0.32

0.38±0.46

4.1±0.42

2.84

0.16

253.4

2.50

0.50

4.00

2.5±0.16

0.14±0.14

4.2±0.12

2.94

0.06

122.1

2.25

0.75

4.00

2.2±0.19

0.61±0.25

4.1±0.18

2.49

0.51

69.76

2.00

1.00

4.00

2.0±0.067

0.67±0.071

4.2±0.010

2.33

0.67

77.99

a)

EDX maps done on FEI Titan 200kv S/TEM with an average of 50 particles analyzed.

The calculated SAR values shown in Table 1 illustrate the vastly different affect
both composition and dopant concentration have on the energy transfer efficiency of a
material. This is especially noticeable in the case of cobalt-substituted ferrite where a large
peak in SAR (734.4 W/g) is seen at a very specific concentration. Interestingly, this peak
corresponds with a large shift in peak loss frequency when examining the material using
AC magnetometry (figure 4).
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Figure 4. Imaginary susceptibility peak frequency as a function of cobalt loading.
This indicates a shift in the effective anisotropy of the material to a higher value
reaching a maximum at an optimal non-stoichiometric concentration of Co. This trend is
also seen in the other doped ferrites including Mn where a peak in SAR value is seen at
lower concentrations of the dopant material (679.2 W/g at [Mn] = 0.19) above which a
large drop in SAR is observed (134 W/g at [Mn] = 0.56). It is obvious then that the
optimization of these materials for MagMED should not be based on stoichiometric
ferrites, but their substituted counterparts. It is also of note that the SAR values calculated
of the metal ferrites were done in toluene and without surface modification. Both the
medium chosen for SAR measurements as well as surface chemistry, especially large
macromolecules such as poly(ethylene glycol), may very well have effects on the overall
energy transfer efficiency of the material.
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The increase in research of these complexly doped systems has given insight into
maximizing the anisotropy of materials, including the partial doping of systems versus the
stoichiometric equivalents.12 Although investigation of these complex materials is
warranted, there are still disagreements in literature pertaining to anisotropy constants and
optimum particles for less complex systems, such as magnetite or pure phase metal
ferrites.13-18 Many of these differences in effective anisotropy can be attributed to
differences in chosen field and frequency parameters or synthesis method resulting in
variable phase purity, particle size dispersion, and clustering effects. This large amount of
variety in chosen parameters is illustrated in Table 2 which shows a large number of values
across the field space.
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Table 2. Summary table of reported parameters related to MagMED
Composition

Diameter
[nm]

Fe3O4

a)

Synthesis

SAR
[W/g]

Max Field
[kA/m]

Max
Freq.
[kHz]

Sample Type

Reference

8.3

TD

6.5

12

183

S.Toluene

12

Fe3O4

19

TD

2452

29

520

Aqueous

19

Fe3O4

30

TD

2614

.66

1000

Aqueous

20

Fe3O4

20

CP

1048

36.5

341

Aqueous

21

Fe3O4

20

CP

719

36.5

341

Solid

21

γ-Fe2O3

24

Pol

1992

21.5

700

Aqueous

22

Co0.6Fe2.4O4

8.4

TD

40.4

12

183

S.Toluene

12

CoFe2O4

28

EC

133

40

101

Aqueous

23

Co0.5Zn0.5Fe2O4

19

CP

115

26.7

256

Aqueous

24

Mn0.8Fe2.2O4

16.1

CP

103.4

2.3

1950

Aqueous

25

MnFe2O4

7.13

Pol

1.8

33.3

276

Aqueous

4

NiFe2O4

7.8

ST

189

25

765

S. DMSO

5

Ni0.8Fe2.2O4

15.8

ST

326

25

765

S. DMSO

5

MgFe2O4

20

CB

85.6

26.7

265

Aqueous

1

Zn0.4Fe2.6O4

15

TD

432

3.7

500

Aqueous

26

4
ZnFe2O4
8.4
Pol
28.19
33.3
276
Aqueous
a)
TD=Thermal Decomposition, EC=Electro Chemical, SG=Sol-Gel, CP=Coprecipitation,

CB=Combustion, ST=Solvothermal, Pol=Polyol Method

b)

Many of the cited papers

demonstrate SAR dependence on field and frequency. This chart only records the largest
field and frequency used, or field reported with SAR values. c)An extended table is available
in the appendix.

These vary widely in literature which is a problem, as it is difficult to accurately compare
or evaluate materials for MagMED when major parameters such as field and frequency
differ. Further aggregation of values reported in literature and standardization of these
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parameters would be beneficial in parsing out materials best suited for clinical application.
It is also important to understand the implications that particle synthesis has, and it may be
of interest to derive the expected Keff value of a material for a given synthesis technique.
This would both allow for easy comparison of newly prepared particle systems as well as
comparison of a specific material between the multiple synthesis routes.

Focus on cobalt substituted Ferrites
From the initial one pot synthesis and characterization of the metal ferrites, the
cobalt ferrite had the largest SAR value, as well as homogenious loading throughout the
lattice of the substituted cobalt. This along with cobalt ferrites already high anisotropy led
us to focus on the cobalt system. Traditionally, research in MagMED has been centered on
the most commonly studied iron oxide phases, maghemite (𝛾-Fe2O3) and magnetite
(Fe3O4). Despite significant research activity, there are currently limited commercial and
clinical applications of these materials. Recently, to improve upon the material properties
of iron oxides, researchers have begun to consider substituted and doped ferrites 1-5. These
materials show a wide range of magnetic properties, including, tunable magnetic
saturation, magnetocrystalline anisotropy, and blocking temperature. 6 Coupled with recent
advancements in synthesis, and increasing control over both size and morphology of
nanoscale colloids, these new materials have been shown to exhibit properties that are
greatly improved from those of Fe-ferrites. One of these select materials is cobalt ferrite
(CoFe2O4), which has a much greater effective anisotropy due to the replacement of the
Fe2+ with the highly anisotropic Co2+ ions.7, 8 By maximizing the effective anisotropy
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through Co doping, specifically between cobalt levels between 0.4 and 1 in Co xFe3-xO4, as
well as identifying the optimal volume for energy release using a novel extended LaMer
synthesis, the optimization of cobalt ferrite based materials for application in MagMED is
possible.9, 10 Herein, we describe a potential synthetic method to produce these materials
in a size controllable manor, and the resulting properties of the particles relating to
MagMED.

Extended LaMer Synthesis of Cobalt Ferrite
Metal oleate complexes used for the extended LaMer synthesis were produced via
a truncated one-pot synthesis as is described by Vreeland et al. Initial data suggested that
particle nucleation and formation began approximately 40 minutes into the reaction
equating to 2 ml of 0.22 M precursor (44 µmols) with the first measurable SAR value
occurring at 50 minutes when particle size was 10.8 nm (657 nm 3). Growth of particles
continued up to 80 minutes, reaching a final diameter of 21.5 nm (5225 nm 3) with a sharp
decrease in particle diameter to 14.8 nm (volume 1683 nm 3) at 85 minutes. This drop
may correlate with the sudden decrease in the SAR value at the 85 minute time point as
seen in figure 5.
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Figure 5. Extended LaMer growth of Co0.5Fe2.5O4 nanoparticles over time with
particle volume determined by SAXS analysis compared to SAR values. Particle volume
is linear up to 85 minutes. SAR shows no discernable trend. Linear best fit lines exclude
the last point in the data shown.

SAXS analysis of this extended LaMer growth (Co 0.5Fe2.5O4) was consistent with
linear volumetric growth with time of 160.8 nm 3/min with an R2 value of 0.99 and a
sudden decrease in nominal particle size at 85 minutes. The best-fit line indicated an
induction time of 46 minutes prior to the start of growth, although this may not account
for possible initial rapid catalytic growth via the Finke-Watzky mechanism. 27
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Figure 6. SAXS data for the extended LaMer drip of Co0.5Fe2.5O4. A1 corresponds to
20 minutes into the reaction. Aliquots were taken every 5 minutes up until the final at 95
minutes. A) Intensity vs scattering vector (q) as the reaction progresses. B) Size
distribution of particles at particular aliquots showing particle growth. Scattering data
was first able to be fit at A6 showing small crystallites using a truncated gaussian.
Subsequent aliquots show small dispersion until A14 where the distribution widens and
shifts to a lower diameter.

The observed decrease in average particle size may occur as a result of reaching a critical
size at which the nanoparticles precipitate from solution and the further subsequent
addition of precursors results in secondary nucleation. This is of high importance as it
shows that the extended LaMer synthesis for magnetite ported to a more complex ferrite
system and needs to be fine-tuned to support each material on a case-by-case basis.
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Although this instability was observed, SAXS and TEM data shows that Co 0.5Fe2.5O4
particles with diameters between 10 nm and 18 nm can be synthesized reliably using this
method without major colloidal instabilities. SAXS data for the LaMer reaction shown in
figure 6.

The instability of the particles at approximately 18 nm also leads to an interesting
phenomenon where a secondary nucleation phase occurs. This is illustrated in figure 7
where we see the TEM images and the corresponding size analysis show a bimodal
distribution with the primary distribution falling around the smaller (6 nm) diameter
particles and a secondary distribution at a much larger size (17 nm). This may be in part
due to the destabilization of particles happening at a fast enough rate that growth kinetics
of particles still in solution cannot consume free metal monomer fast enough, allowing
for a buildup in monomer concentration. This may lead to secondary nucleation event.
Initial attempts at remedying this issue were made by lowering flow rate of the precursor
injection. A 1 ml/hr flow rate caused issues with the synthesis itself as both the slow flow
of N2 gas and taking usable aliquots caused the reaction to “dry up” before meaningful
data could be extracted. The 2 ml/hr flow rate produced particles that were
inhomogeneous in both shape and size further exacerbating the issue with the
inhomogeneity seen in the 3 ml/hr drip rate. It must be noted
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Figure 7. TEM and the corresponding size analysis distribution of aliquots taken during
extended LaMer reaction synthesizing Fe2.5Co0.5O4. A) 80 minutes diameter=12.4 nm,
standard deviation=1.1 nm. B) 100 minutes, diameter= 16.0 nm, standard deviation= 1.4
nm. C) 120 minutes diameter= 17.4 nm, standard deviation= 1.8 nm. D) 140 minutes,
diameter small= 6.54 nm, standard deviation small= 2.3 nm, diameter large= 17.4 nm,
standard deviation large= 1.2 nm. All scale bars are 50 nm.

that there are many additional variables to change including precursor concentration,
capping ligand concentration, reaction temperature etc. and that exploration into the
optimization of this synthesis is ongoing.

62

SAR vs. Particle Size
One of the many advantages in using an extended LaMer synthesis is that particle
size can be controlled, and once a desired size is reached, the reaction can be quenched
yielding a sample with relatively low dispersion and high uniformity. Alternatively, small
aliquots can be taken throughout the reaction to isolate size as a lone variable. Expectedly
as the reaction proceeds, the particles get larger and the SAR of the samples increases
which can be seen in Figure 5. However, the SAR values calculated from the drip
reaction aliquots were surprisingly low, with the highest at approximately 50 W/g.
It is important to note that the diameters given in this chapter (both TEM and
SAXS) may not represent the true magnetic diameter. The particles may contain a
relatively large magnetic dead layer which has been seen in iron oxide particles, which
may explain the low SAR values exhibited by these particles. 28 The low SAR values may
also be artificially lowered due to the presence of unreacted precursor still left in the
sample during measurement. Because of the constant drip of oleate precursor it is
inevitable that some is taken up in each of the aliquots. Although chromatography was
done to try and minimize this, it is difficult to fully separate all excess oleic acid and
metal oleate from the particle sample. Any excess metal not incorporated into a particle
would not contribute to the heating rate during calorimetry but would show up in the
mass normalization, thus leading to an artificially low specific absorption rate. A longer
drip reaction was run to confirm the SAR value limit as well as to see the effects of the
secondary nucleation. As the reaction progressed an expected increase and unexpected
sudden drop in SAR was seen, similar to previous reactions. What is interesting to note is
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that a secondary increase and sudden drop in SAR was seen again after the first SAR
increase and decrease cycle. This illustrates that the drip reaction under these conditions
(Fe2.5Co0.5O4 @ 3ml/min) showed an almost oscillatory effect through nucleation
growth and destabilization seen in figure 8. These phenomena limit the usefulness in
using this specific reaction with these parameters to synthesize large diameter particles
but applications looking for size control of cobalt doped ferrites within the 10 to 20 nm
regime may find the presented synthesis useful.
Investigation into different ligands, drip rates and precursor concentrations could
potentially alleviate the secondary nucleation by changing the energetics allowing the
particles to stay in solution, or change the metal monomer addition rates to eliminate
secondary monomer buildup and nucleation.

64

Figure 8. Extended specific absorption rate as a function of reaction time showing
oscillatory behavior from multiple nucleation, growth, and precipitation cycles.

Conclusions
Non stoichiometric metal ferrites have been synthesized via the one pot method
and characterized via TEM, EDX, ICP and SAR to evaluate their usefulness in MagMED
applications. EDX was of particular importance as it showed that morphology may play a
large role in the determination of anisotropy and therefore heating rate. Cobalt doped
samples showed high SAR values between Fe2.5Co0.5O4 and Fe2.4Co0.6O4. This material
was investigated further using the extended LaMer drip synthesis to control size and
evaluate it as a possible candidate for a high SAR material.
Size control up to approximately 20 nm was achieved using the Extended LaMer
drip however a cyclic nucleation, growth, and destabilization was seen using both TEM
and SAR values which limits the size. Further exploration into the experimental drip
procedure must be done to optimize the synthesis as particle stability above 20 nm
leading to secondary nucleation was observed. Initial experiments into changing the flow
rate of precursor show promise but a more detailed exploration of drip rate, precursor
concentration, and stabilizing ligand are necessary.
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CHAPTER THREE
GLYCAN FUNCTIONAL MAGNETITE AS A NOVEL UNCONVENTIONAL
ANTIBIOTIC
Contribution
This chapter is adapted from the article; Multianchored Glycoconjugate-Functionalized
Magnetic Nanoparticles: A Tool for Selective Killing of Targeted Bacteria via Alternating
Magnetic Fields, Y. S. Raval, B. D. Fellows, J. Murbach, Y. Cordeau, O. T. Mefford, T.R.
J. Tzeng, Adv. Funct. Mater. 2017, 27, 1701473.1
This article is a shared first author publication between myself and Dr. Yash Raval.
It is acknowledged in the article that equal work was done between the two individuals.
My contribution to this manuscript was the design, synthesis, and characterization of the
nanomaterials. This includes synthesis of the polymer, conjugation of the glycan, and all
characterization of the material. I was also paramount in the design and application of the
MagMED treatment of the bacterial cultures, as well as stability studies, and TEM of both
the particles and the bacteria. The manuscript was also written as a joint effort with Dr.
Yash Raval. I would like to extend a large acknowledgement and thank you to Dr. Yash
Raval and Dr. Tzuen-Rong Jeremy Tzeng from the Clemson Microbiology Department.
Without them the highly complex and collaborative nature of this work would not be
possible. I would also like to thank Jamie Murbach, and Yves Cordeau from the Clemson
Materials Science and Engineering Department for help in the intricate synthesis of some
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of the materials required for this project. Lastly, I would like to thank my advisor Dr. O.
Thompson Mefford, who was the guiding hand for all of the materials synthesis,
characterization and application for the work I completed on this project.
Introduction
The emergence of anti-microbial resistance (AMR) bacteria has quickly taken hold
as one of the greatest threats to modern medicine on a global scale, and the ramifications,
if not dealt with in a timely manner, may be catastrophic. Currently, there are more than
160 different kinds of antibiotics available for therapeutic purposes. 2 However, unrestricted
and prolonged usage of antibiotics has resulted in rapid emergence of new strains of
bacteria that have developed resistance to these drugs and, over time, evolved as multidrug resistant microorganisms. Infections caused by such bacterial strains have resulted in
prolonged hospital stays and an increase in outpatient costs and patient mortality and
morbidity throughout the world.3 In a World Health Organization (WHO) global report on
antimicrobial resistance, it is stated that AMR is a complex global public health challenge
and that no single or simple strategy will contain the emergence and spread of AMR
infectious organisms.4 A recent study by the US Center for Disease Control and Prevention
estimates that every year, diseases caused by AMR strains of bacteria infect millions of
people in the US, and thousands of them die annually due to lack of new antibiotics. 5 The
emergence of AMR also has an enormous socioeconomic impact. A 2014 report from
RAND Europe, estimates the economic cost of AMR to be approximately 3.1% of global
output gross domestic product (~2.4 trillion US dollars).6 Although recognized as an
immediate issue, antibiotic discovery has declined with many major pharmaceutical
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companies discontinuing their antibiotic development programs over the past decade due
to low return on investment and difficulties in identifying new compounds. This reinforces
the need for development of novel therapeutic approaches to address the AMR challenges. 79

Nanoparticles have been a highly investigated area as their properties differ from
their bulk counterparts. Of these materials, iron oxide has found particular prevalence in
the biomedical field with use in MRI contrast, drug delivery, cell separation, and cancer
therapy.10-12 When an iron oxide particle is subjected to an alternating magnetic field, a
hysteresis loop is completed in which the area relates to the energy release per cycle. 13 By
doing this at relatively high frequencies (kHz-MHz), the amount of energy transfer is great
enough to affect surrounding cells.14 This phenomena was previously referred to as
magnetic hyperthermia due to an observed temperature rise. However, recent studies have
shown that cell death could be induced in the absence of bulk heating of the environment. 14,
15

In seeking a more descriptive term, we and others prefer to use the phrase magnetically

mediated energy delivery (MagMED).16,

17

The use of nanoparticles for biological

applications requires stringent attention to surface chemistry as it affects reactivity, biodistribution, and stability.10,

18

Much research has been put into optimizing surface

chemistries for nanomaterials, with poly(ethylene oxide) (PEO) being one of the
universally accepted coatings.19 PEO has been shown to prolong circulation time, greatly
improve stability in protein and ion-rich environments, impart secondary functionality, and
render stealth from the immune system.19 Further enhancement in stability may be imparted
using a multi-anchored catechol as the iron binding moiety.18, 20 This is highly necessary
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as desorption of the polymer coating is an issue with many biomolecules including
phosphonates and peptides, which have high affinity for iron oxide. 21
Though numerous groups have reported using alternate magnetic field along with
magnetic nanoparticles as an alternative cancer therapy, limited work has been done in the
same direction for treating bacterial infections.22-24 More importantly, to the best of the
authors’ knowledge, no work exploring the use of nanoparticles for selective killing of
targeted pathogen in mixed-bacterial culture settings has been reported. Attachment of
bacterial pathogens onto the surface of mammalian cells is one of the foremost events in
host-pathogen interactions. Several pathogenic bacteria are able to adhere to specific hostcell receptors via carbohydrate binding proteins, also called adhesins or lectins. 25 These
interactions are part of the signal cascade enabling bacteria to recognize the environment
they are in and then turn on the cascade of processes leading to infections. 26, 27 If these
binding interactions are inhibited/interrupted then the chances of getting infection is greatly
reduced.28
The rapid advancement in the fields of nanotechnology and glycotechnology offers
potentially new therapeutic options for treating bacterial infections. Over the last few years,
few research groups have studied nanomaterials functionalized with multivalent
carbohydrate groups and synthetic glycoconjugates for probing bacterial lectincarbohydrate interactions.29, 30 Attaching these molecules onto the surface of nanomaterials
has found numerous applications in pathogen detection/targeting, 31 mammalian cellreceptor mimicking,32 drug delivery,33 and in anti-adhesion therapies.34 Specifically,
carbon nanotubes,35,

36

gold nanoparticles,37,
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38

diamond nanoparticles,39 polymeric

nanoparticles,40 and magnetic nanoparticles41-44 were reported to be bio-functionalized
with different carbohydrate sugars/glycoconjugates and were utilized for studying lectincarbohydrate

interactions

in

different

bacterial

species.

Given

the

excellent

biocompatibility of using glycoconjugates molecules for functionalizing nanomaterials,
not many studies have been carried out that can specifically detect and differentiate
bacterial species in a mixed population both in vitro and in vivo.
Escherichia coli (E. coli) is one of the most common types of bacteria naturally
occurring in the digestive tract of humans and animals. While most of the E. coli strains
are harmless to humans and animals, there are few E. coli serogroups that are mainly
responsible in causing infections. E. coli belonging to the enterotoxigenic (ETEC) group
is responsible for causing traveler’s diarrhea in humans and bloody diarrhea in neonatal
calves, pigs and lambs.45-47 The prevalence of the serogroups and presence of adhesins are
considered to be the primary factors that facilitate intestinal colonization of ETEC. ETEC
adhere to small intestinal microvilli membranes in vivo via adhesins that recognizes
specific carbohydrate receptors and produce enterotoxins that act on enterocytes eventually
causing diarrhea.48 Recently, numerous studies have reported an increase in multi-drug
resistance of ETEC strains associated with the inclusion of growth-promoting antibiotics
in animal feed.49, 50 E. coli K99 (EC K99) is one of the commonly found ETEC strains in
newborn farm animals responsible for causing colibacillosis. 51 EC K99 has unique
adhesins that can specifically recognize and attach to sialic-acid based glycolipid receptors
present on the ileal villus epithelium of the small intestine.52, 53 If these binding interactions
are inhibited/interrupted, the chances of getting infection are greatly reduced. Our previous
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studies have shown that nanoparticles functionalized with specific sialic-acid derivatives
resulted in nanoparticles-induced aggregation of EC K99 along with excellent
biocompatibility.37, 42
In this study, it is hypothesized that multi-anchored magnetic nanoparticles
conjugated with sialic-acid moieties that mimic host-cell receptors specific for EC K99
adhesins, would induce rapid clustering of EC K99 in the presence of these nanoparticles,
and when such bacteria-nanoparticles aggregates are exposed to AMF, it would result in
enhanced and selective inactivation/killing of EC K99. Our results demonstrate a clinically
significant ~3-log reduction in CFU54 of EC K99 in the presence of GM3-MNPs used in
conjunction with AMF. To our knowledge, it is for the first time that sialic-acid derived
glycoconjugate functionalized magnetic nanoparticles have been employed for specific
killing of target bacteria in the presence of AMF. This study serves as proof-of-concept
that a high degree of selective bacterial killing can be obtained without using traditional
antibiotics.

Experimental
Synthesis of Magnetite Nanoparticles
Magnetite nanoparticles were synthesized via thermal decomposition of an
organometallic precursor in a high boiling point organic solvent. 55 Iron (III)
acetylacetonate (Alfa Aesar, 99%) (1.074g) was combined in a 3-neck round-bottom with
oleic acid (Alfa Aesar, 90%) (15ml) serving as both the solvent and the stabilizing ligand.
The vessel was initially purged with N2 after which flow was adjusted to 0.1 L/min
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ensuring an inert environment. The vessel was then heated to 350°C and left to react for
3 hours. At 3 hours, the reaction was quenched by removing it from heat, and left to cool
under inert atmosphere. The resulting particles were dispersed in minimal hexanes and
precipitated using a mixture of 3:1 ethanol (Fisher, Anhydrous) to acetone (Alfa Aesar,
99.5%) (x3). Particles were dispersed in toluene (VWR, 99.5%) and run through an
organic based GPC column (Bio-rad S-X polystyrene beads) to further remove excess
oleic acid ligand.56 TEM and size analysis was then done on the particles to ensure size
specificity (figure 1).

Figure 1. Magnetite nanoparticles as synthesized before functionalization with PEO-PAAdopamine polymer. A) Representative TEM image of the particles. B) Histogram depicting
the particle size distribution.
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Synthesis of Alkyne-PEO-PAA-Dopamine.20
Poly(ethylene oxide) (PEO) synthesis: Ethylene oxide (Sigma Aldrich, 99.9%)
distilled into a high pressure Parr reactor. Na-benzylphenone still dried tetrahydrofuran
(THF, EMD Millipore, 99.9%) was injected along with a predetermined amount of an
anionic initiator potassium bistrimethyl silyl amide (Sigma Aldrich, 1M in THF). The
reaction was allowed to run for 72 hours and was subsequently terminated by opening the
reactor to atmosphere. The synthesized PEO was precipitated with diethyl ether (VWR,
99.9%) and washed (3x) by dispersing it in chloroform, precipitating the polymer,
centrifuging it at 15,000 RCF for 10 minutes and pouring off the residual supernatant.
The PEO was then dried under vacuum overnight. HNMR was performed to calculate
molecular weight as well as to confirm the presence of the protected amine end-group.
Under dry N2 atmosphere, hetero-functional PEO and sodium hydride (Sigma Aldrich,
95%), in slight excess, were dissolved in dry THF. This was allowed to react for 30
minutes before an excess of propargyl bromide (Sigma Aldrich, 80% in toluene) was
added drop-wise to the solution over 15 minutes. Once all of the propargyl bromide was
added, the solution was allowed to stir for 12 hours at room temperature. The polymer
was then purified by dissolution in chloroform and precipitation with diethyl ether (x3)
and dried under vacuum for 12 hours. HNMR was performed to confirm the presence of
an alkyne.
Deprotection of the trimethyl silyl group was done in 1M hydrochloric acid
(VWR) in methanol (VWR, 99+%) and allowed to react for 4 hours. The polymer
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methanol solution was diluted with DI water and the deprotected PEO was extracted (3x)
with 50ml chloroform from which it was precipitated with diethyl ether and dried under
vacuum. HNMR was performed to confirm the loss of the trimethylsilyl group.
Coupling of the PEO to the poly(acrylic acid) (PAA, Sigma Aldrich Mn=1,800) was done
by dissolving both in dry N,N-dimethylformamide (DMF, Sigma Aldrich, 99.8%) in a 5:1
ratio. To this 1.1 excess (N-(3-dimethylaminopropyl)-N’-ethylcarodiimide hydrochloride
(EDC, TCI, 98%) as well as catalytic amounts of 4-(dimethylamino)pyridine (DMAP,
Alfa Aesar, 99+%) were added. The solution was allowed to stir for 12 hours. The
solution was filtered, further purified by dissolution in chloroform following precipitation
with diethyl ether (x3) and then dried under vacuum. HNMR was done to confirm PEOPAA coupling.
Attachment of the anchor group: Dopamine hydrochloride (Alfa Aesar, 99%) was
dissolved in DMF along with a 10% molar excess of triethylamine (Alfa Aesar, 99%) and
allowed to stir for 30 minutes. In a separate round-bottom the PEO-PAA was dissolved in
DMF along with EDC and catalytic amounts of DMAP. To this the dopamine
hydrochloride solution was added and the combined solution was allowed to stir for 12
hours. The solution was then filtered, purified by dissolution in chloroform then
precipitated in diethyl ether. The final product was dried under vacuum and analyzed to
confirm the presence of the catechol.
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Ligand exchange18
Both magnetite nanoparticles as well as the PEO-PAA-dopamine were suspended
separately in 5ml of chloroform. The particles at an approximate concentration of 3mg/ml
of Fe and the polymer at approximately 40mg/ml. The polymer was then transferred to a
scintillation vial capped with a septum and placed in a sonication bath. The bath was
turned on and over the course of 15 minutes the magnetic nanoparticle solution was
injected into the polymer solution. Once injection was finished, the combined solution
was allowed to further sonicate for 15 minutes. The solution was then removed and put
on a shaker table for 72 hours. The chloroform was then removed via rotary evaporator
and further dried under vacuum. Deionized water (DI H2O) was then added and the vial
was sonicated to help mediate suspension into the water. The water-based particles were
then filtered through a 0.2-micron nylon filter to ensure large aggregates were not
present. The solutions were then run through a GPC column (Bio-Rad P polyacrylamide
beads) to separate excess polymer from the water dispersible particles.

Click Chemistry57
The Cu(I) catalyzed Huisgen 1,3-dipolar cyclo-addition between the terminal
polymer alkyne and the azido-GM3 was done in the aqueous phase with the azido-GM3
being the limiting reagent. A 2 mol % solution of Cu(II) sulfate (Sigma Aldrich, 99%)
was combined with equivalent molar amounts of the THPTA (synthesized according to
Hong et al.) Cu chelating ligand and let to react for 10 minutes. 58 This was then
transferred into the aqueous alkyne-particle suspension and the azide-GM3 was then
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added. After both additions a 10 mol% aqueous solution of (+)-sodium L- ascorbate
(Sigma Aldrich 98+%) was added to facilitate the reduction of Cu(II) to Cu(I). The click
reactions were left at room temperature for 12 hours, and were then purified using size
exclusion chromatography.56

Fourier transform infrared (FTIR) spectroscopy
Fourier transform infrared (FTIR) spectroscopy microscopy was done using a
Thermo-Nicolet Magna 550 FTIR spectrometer equipped with a Thermo-NicPlan FTIR
microscope. 16 Scans were done for both the sample and the background. Samples were
prepped by dropping a small amount of the water suspended sample on a germanium
plate and left to dry under a heat lamp for 20 minutes. FTIR was done on the resulting
films (figure 2).
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Figure 2. FTIR spectra of particles before GM3 conjugation (A), GM3 molecule (B), and
after conjugation (C). The lack of the azide peak in C at 2100 cm-1 indicates purification
of unbound GM3 after conjugation was successful.
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Iron Concentration Determination
50 μl of magnetite suspension was dissolved in concentrated HCl, reduced and
complexed with 1,10-phenanthroline (Sigma-Aldrich, 99%). UV-VIS was then
performed to determine the amount of iron in the known volume. 59, 60

Transmission Electron Microscopy (TEM) of Bacterial Strains
Post AMF treatment of bacterial cells (MNPs concentration - 650 μg/ml), the
mixture samples were removed from the glass vial and centrifuged at 7000 x g for 5
minutes. Later, the supernatant containing unbound MNPs was removed and the pellet was
washed with 1x PBS in repetitive centrifugation cycles (3 times). After the final wash, the
pellet containing MNPs and bacteria was fixed in cacodylate-buffered glutaraldehyde (3%,
pH~7.2; Electron Microscopy Sciences, PA, USA) at 4°C for 12 hours. Subsequently, the
sample was again washed in the cacodylate buffer thrice. 5 μl of the sample was dropped
onto carbon-coated copper grid and was allowed to air dry for 4 hours. Finally, the sample
was stained with 2% uranyl acetate (Electron Microscopy Sciences, PA, USA) solution for
15 seconds and blotted dry with filter paper.

AMF Treatment of Bacterial Strains in the presence of MNPs
As reported in our previous study,42 E. coli K99 (EC K99) was transformed with
plasmid pGREEN (Carolina Biological Supply Company, NC, USA) carrying ampicillinresistance marker gene. Avirulent E. coli O157:H7 strain B6914 (EC O157) was
modified to be rifampicin resistant (100 μg/ml; TCI America, OR, USA) through
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gradient-plate technique as previously described.61 EC K99 strain was routinely grown in
tryptic soy broth/tryptic soy agar (TSB/TSA; EMD Millipore, MA, USA) supplemented
with ampicillin (100 μg/ml; TCI America, OR, USA) and EC O157 strain was grown in
tryptic soy broth/tryptic soy agar (TSB/TSA) supplemented with rifampicin (100 μg/ml).
For AMF treatment experiments, bacterial cultures were grown overnight under shaking
conditions (250 rpm) at 37°C in TSB supplemented with appropriate antibiotics. Later,
the bacterial cells were washed and centrifuged thrice in 1X sterile phosphate buffer
saline (PBS). Approximately, 5 x 107 CFU of bacterial cells were suspended in 1X PBS
based on optical density (OD600) readings. Both the bacterial strains were mixed with
different types of MNPs and at different concentrations of MNPs in a sterile
microcentrifuge tube and this mixture was incubated at room temperature for 30 minutes
under gentle shaking conditions to facilitate the binding interactions between bacterial
adhesins and MNPs.42 At the end of incubation time-period, the mixtures of MNPs and
bacteria were transferred to sterile glass vial. This vial was then placed in chamber of the
alternate magnetic field generating instrument (EasyHeat Induction Heating System Ameritherm©) that is covered with 5-turn induction coil, which was connected to
polycarbonate recirculating water-bath for maintaining the sample temperature (37°C). 62
A fiber-optic temperature probe (Neoptix™) was inserted inside this chamber to
continuously monitor the temperature. The working conditions of the AMF instrument
for the experiments were as follows: 480 Amps current, 207KHz frequency and magnetic
field strength of 31 KA/m. The field was measured using an AC magnetic field probe
(AMF Life Systems, Auburn Hills, MI). The vial containing the mixture of MNPs and
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bacteria was then exposed to AMF treatment for different durations (30, 60, and 120
minutes). Different groups of control experiments were as follows: 1) mixture containing
only bacterial strains suspended in 1X PBS; 2) mixture containing bacteria and MNPs but
no AMF exposure. After AMF treatment, the above-mentioned mixture was serially
diluted in 1X sterile PBS and 100 μl of sample from each dilution tube was spread-plated
onto sterile TSA petri plates supplemented with appropriate antibiotics. Later, the TSA
plates were incubated overnight at 37°C. Finally, the grown colonies on the TSA plates
were counted and compared with control group plates and the reduction in colony counts
was expressed as colony forming units per ml.

AMF Treatment of Mixed Bacterial Cultures in the presence of MNPs
To determine the targeted specificity of GM3-MNPs against EC K99 in mixedculture conditions, both the strains of EC K99 (concentration - 5 x 107 CFU) and EC
O157 (concentration - 5 x 107 CFU) were mixed in a single microcentrifuge tube. GM3MNPs (650 μg/ml) were added to this mixture and the tube was incubated for 30 minutes
at room temperature under gentle shaking conditions. Later, AMF treatment (time - 120
minutes) was applied to this tube as mentioned earlier. Control groups included 1) adding
PEO-MNPs to mixture containing both strains of bacteria in the same tube and
exposing/not exposing them to AMF; 2) adding GM3-MNPs to tube containing both
bacterial strains but no AMF; 3) AMF exposure to tube containing only bacterial strains
and no MNPs. Post-treatment, this mixture was serially diluted in 1X PBS and 100 μl of
each dilution was spread plated in triplicates onto TSA plates supplemented with
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appropriate antibiotics. The petri plates were incubated overnight at 37 °C and CFU
reduction was compared to control group plates.

Bacterial Live/Dead Fluorescence Assay
To qualitatively determine the cell membrane integrity of bacterial cells,
Live/Dead fluorescence assay were performed using BacLight™ Bacterial Viability Kit
(L7007, Molecular Probes, Invitrogen, OR, USA). Freshly grown cells of EC K99 and
EC O157 (5 x 107 CFU) in 1X PBS were mixed with PEO-MNPs and GM3-MNPs
(Concentration - 650 μg/ml) separately in different microcentrifuge tubes. The mixture
was allowed to incubate at room temperature for 30 minutes with gentle mixing after
every 5 minutes. The tubes were then exposed to AMF therapy for 120 minutes. The
samples were then prepared according to manufacturer’s protocol. Later, both fluorescent
dyes i.e. SYTO 9 and Propidium Iodide were added to the samples. Finally, the samples
were viewed under fluorescence microscope under different filters (SYTO 9 Excitation/Emission - 485/510 nm; Propidium Iodide - Excitation/Emission - 485/630
nm) at 400X magnification. The images obtained under different filters were merged in
ImageJ software (NIH, USA). Control group samples were not exposed to MNPs/AMF.

Microbial ATP Cell-Viability Assay
To measure the overall intracellular ATP levels of bacterial species (EC K99 and
EC O157) before and after AMF treatment in the presence/absence of MNPs
(concentration - 650 μg/ml, AMF treatment time - 120 minutes), microbial BacTiter-
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Glo™ (Promega, Madison, WI) assay kit was used. 24 The assay was performed according
to manufacturer’s protocol with a small modification for samples containing MNPs. At
the end of this assay, the plate was read in a micro-plate reader with luminescence
capability (Synergy Hybrid H1, Biotek®) and the obtained results were expressed in
relative luminescent units (RLUs).

Statistical Analysis
All the statistical analysis was performed using Graphpad Prism software (V 5.0,
CA, USA). All the experiments were done in triplicates and data are expressed as
Mean±SD. Statistically significant differences between the groups were evaluated by
performing ANOVA. Post hoc group comparisons were calculated through Bonferroni
post-tests. Results showing P values of ≤0.05, <0.01, and <0.001 were considered to be
statistically significant.

Results and Discussion
Synthesis of GM3-MNPs
Magnetite nanoparticles were synthesized using a one-pot thermal decomposition
of iron (III) acetylacetonate and oleic acid.59, 63 Particles had an average diameter of 23.7
nm with a standard deviation of 1.55 nm (Figure 2). The moment vs. field (MvH) (Figure
3) measurement was done on the particles to confirm the super-paramagnetic behavior of
the MNPs.
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Figure 3. Moment vs. Field (MvH) loop showing the superparamagnetic behavior of the
magnetite nanoparticles (Msat ~ 53 emu/g Fe).

Polymer design was based on work by Stone et al. where a multi-anchored
binding approach showed increased stability in comparison to polymer ligands with a
single binding moiety (Figure 4).20 In this work, however, the chosen catechol was not
nitroDOPA but dopamine.
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Figure 4. Left: 1) Anionic ring opening of ethylene oxide, 2) alkyne functionalization with
propargyl bromide, 3) deprotection of primary amine, 4) coupling of PEO to PAA, 5)
coupling of dopamine hydrochloride to the PEO-PAA. Right: Click reaction between
polymer coated particles and GM3 molecule.

By using the multi-anchored approach, the stability in salt and protein buffer solutions is
retained even when using dopamine as the anchoring group. 18, 64 Hydrodynamic diameter
and zeta potential of the PEO-MNPs before and after click-coupling of GM3 are reported
in Table 1.

89

Table 1. Dynamic light scattering and zeta-potential
measurements before and after GM3 conjugation.
Hydrodynamic Diameter Zeta-potential
Z Avg. (nm)
(mV)
def
PEO-MNPs 78.8
-8.73
GM3-MNPs 88.8
-7.68
The specific absorption rate (SAR) value for the MNPs was measured to be 53.4
W/g (bulk temperature rise of solution from 37°C to 42°C), which is similar to the value
for magnetite reported by Ma et al.65 The increase in the hydrodynamic diameter
indicates the GM3 glycoconjugate was successfully coupled to the PEO-MNPs.
Attenuated total reflectance Fourier transformed infrared spectroscopy (ATR-FTIR) also
confirmed the GM3 coupling went to completion with the disappearance of the azide
peak from GM3 at ~2110 cm-1 and the appearance of a broad alcohol peak in the GM3MNPs spectrum from 3620-3170 cm-1 (Figure 2).42

MagMED Inactivation of Bacteria
The efficacy of GM3-MNPs for specific inactivation of ETEC K99 via MagMED
was compared to that of enterohaemorrhagic Escherichia coli (EHEC) O157:H7 strain
since the two strains showed different receptor-binding specificities and EHEC O157:H7
strains are rarely harbored by pigs.66 Another E. coli strain ORN178 expressing mannosebinding type-1 fimbrial FimH adhesins67-71 was also evaluated and served as a negative
control (data not shown). The MagMED inactivation of bacteria was assessed using a
colony forming unit (CFU) reduction assay to determine the number of viable cells
(CFUs) remained after treatment. The efficacy of AMF mediated killing of the target
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bacteria, EC K99, in the presence of GM3-MNPs in a concentration- and time-dependent
manner was evaluated. GM3-MNPs were mixed with EC K99 and incubated at room
temperature for 30 minutes to facilitate the binding between GM3 molecules present on
the surface of GM3-MNPs and adhesin molecules of EC K99.42 PEO-MNPs were used as
an internal control group to evaluate the role of the targeting moiety GM3. The magnetic
field and frequency used in the AMF therapy remained constant for all treatment groups
(31 kA/m and 207 kHz). Figure 5-A shows the final counts of CFU/ml of EC K99 after
treatment.
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Figure 5. Colony Forming Unit (CFU) of E. coli strains after AMF treatment at different
concentrations of MNPs and different time-intervals; A - CFU/ml of EC K99 after AMF
treatment; B - CFU/ml of EC O157 after AMF treatment. Data is expressed as Mean ±
SD (n=3); Statistical analysis – Analysis of Variance (ANOVA); * p-value <0.05, ** pvalue <0.01, and *** p-value <0.001, where the population was compared to control
population).
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The reduction in CFU/ml was found to be both time and MNPs concentration
dependent. After 30 minutes of AMF treatment, ~1-log reduction in CFU/ml of EC K99
was observed at a particle concentration of 650 µg Fe/ml. After 60 minutes of AMF
treatment, a significant ~2-log reduction of EC K99 (p<0.01) was observed for both 280
µg Fe/ml and 650 µg Fe/ml concentrations of GM3-MNPs. Finally, at the end of 120
minutes of AMF treatment, an extremely significant ~3-log reduction in CFU/ml of EC
K99 (p < 0.001) was achieved with particle concentrations of 650 µg Fe/ml. Moreover,
no significant killing of EC K99 was observed in experimental groups not exposed to
AMF (Figure 6-A) indicating the non-toxicity of PEO-MNPs and GM3-MNPs to EC
K99.
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Figure 6. CFU/ml assay to determine viability of E. coli strains in the absence of AMF at
different concentrations of MNPs and at different time-intervals: A - CFU/ml of EC K99
in the absence of AMF; B - CFU/ml of EC O157 in the absence of AMF. Data is
expressed as Mean ± SD (n=3); Statistical analysis – Analysis of Variance (ANOVA).
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Thus, targeted approach in AMF exposure can explain such effective reduction in
CFU/ml of EC K99. Several research studies have shown similar results in reduction of
bacterial population through antibody-targeted photo-inactivation process via nearinfrared laser (NIR) in the presence of nanoparticles in both in vitro and in vivo
settings.72-74 In our previous work, we have shown that sialic-acid sequences of GM3
molecule (Neu5Ac(α2-3)-Gal-(β1-4)Glcβ-sp) can specifically interact with S-type
fimbrial proteins/adhesins present on the outer surface of EC K99 and induce rapid
clustering of EC K99.37, 42 The presence of FanC, a major protein sub-unit present in Stype fimbriae, is primarily responsible for the specific attachment of EC K99 onto the
ganglioside receptors, which are present on the host-cell surface. 75 Therefore, it is likely
that GM3-MNPs-induced bacterial aggregation plays a major role in the applied method.
Since GM3-MNPs are attached to or are in extremely near vicinity of EC K99,
one can expect to see increased delivery of energy from the particles into the bacterial
cells. Some reports have also suggested highly localized temperature increase taking
place in the biological systems in the presence of MNPs when using AMF. 76-78 For
example, Huang et al. functionalized the surface of MNPs with fluorophores that act as
molecular temperature probes while remotely activating ion channels/neurons in the
presence of AMF.79 Also, the observed drug release due to phase changes in the polymer
near the surface of the particle suggests a local temperature increase.80 In these studies,
too, the overall temperature of bulk particle suspensions remained constant or increased
marginally. However, the exact mechanisms of how energy from the particle interferes
with these pathways are still unknown and are in need of better characterization.
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In the present study, the experimental group comprising of 140 µg Fe/ml that underwent
AMF treatment did not show significant reduction in CFU/ml of EC K99 after 120
minutes of exposure. One possible explanation for this might have to do with the number
of particles present in different concentrations of the GM3-MNPs. The lowest
concentration group would have the least amount of MNPs. Thus, they might not be able
to efficiently deliver the energy of the MNPs into the bacterial cells. PEO-MNPs at all
concentrations and all time-points did not induce significant decrease in the colony
counts of EC K99.

MagMED Inactivation of EC O157
Figure 5-B shows the overall reduction in CFU/ml of EC O157 after exposure to
AMF in the presence of PEO-MNPs or GM3-MNPs. A ~1-log reduction in CFU/ml was
observed with both PEO-MNPs and GM3-MNPs at particle concentration of 650 µg
Fe/ml for 60 and 120 minutes. All other MNPs concentrations and time-points showed no
significant reduction in colony counts of EC O157. No reduction in CFU/ml of EC O157
was observed in the absence of AMF (Figure 6-B) indicating the non-toxicity of PEOMNPs and GM3-MNPs to EC O157. Several groups have observed certain degree of
non-specific electrostatic interactions occurring between bacteria and nanoparticles when
mixed with relatively higher concentrations of nanoparticles. 81, 82 Hence, it is possible
that due to such non-specific interactions along with high MNPs-to-bacteria ratio, few
MNPs might come in contact or close proximity with EC O157 resulting in delivery of
some magnetic energy into these cells causing a limited ~1-log reduction in CFU.
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Bacterial control groups exposed to AMF in the absence of MNPs showed no changes in
the overall CFU/ml after 120 minutes of exposure indicating little to no effect of AMF
itself on the cultures.
Recently, Nguyen et al. conducted a similar type of study wherein they showed
that iron-oxide nanoparticles could rapidly induce biofilm dispersal in Pseudomonas
aeruginosa (P. aeruginosa) through application of an alternating magnetic field.24 Their
study showed rapid increase in the temperature of buffer solution when nanoparticles
were mixed with them and exposed to magnetic field. Similarly, another study reported
4-log reduction in biofilm of P. aeruginosa when exposed AC magnetic field in the
presence of iron-oxide nanoparticles.23 The authors have attributed this reduction in
biofilm due to quick increase in bulk temperature of the system through magnetic
hyperthermia. Thomas et al. used magnetic fluid hyperthermia in the presence of
carboxylic-acid stabilized iron-oxide nanoparticles and achieved ~7-log reduction in
population of Staphylococcus aureus.22 In all of the aforementioned studies, the
killing/inactivation of bacterial species/biofilms was attained solely due to drastic
increase in the bulk temperature of the working system through nanoparticles and
hyperthermia. It would be worthwhile to note that the aforementioned studies were
conducted in the presence of relatively high concentrations of MNPs (ranging from 1
mg/ml to 50 mg/ml) and higher instrument frequencies (e.g., up to 1.05 MHz). Using
such high concentrations of MNPs in humans might cause serious concerns with regard
to toxicity of MNPs. Also, none of the above listed studies utilized any kind of targeting
moiety on nanoparticles for attaining specificity.
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On the other end, this work demonstrates significant killing of EC K99 at much
lower concentrations (maximum concentration - 650 µg Fe/ml) and at relatively benign
frequencies (i.e., 207 kHz). These results further support our hypothesis that the
combination of magnetic fields and presence of GM3-MNPs are responsible for reduction
in CFU/ml of EC K99 via targeted AMF therapy. The reported CFU reduction within 120
minutes (i.e., 3-log in 2 hours) treatment compares favorably to conventional antibiotic
treatments. For examples, Silva et al. reported that ciprofloxacin at concentrations
corresponding to 1x MIC (Minimal Inhibitory Concentration) reduced E. coli population
by 1-log over a 24-h study while at 2x and 4x times the MIC value, they observed a ~2.5log reduction in the first 2 hours and a 4-log reduction after 24 hours of treatment. 83 In a
similar study, Drago et al. observed no reduction of E. coli population at 1x MIC with
levofloxacin or ciprofloxacin over a 24-h period while a 2-log and 3-log reduction at 4x
MIC was observed 3 hours and 24 hours after treatment, respectively. 84 It is conceivable
that with fine-tuned MagMED treatment regimen, it is possible to improve the treatment
outcomes of infections caused by multiple-drug resistant bacteria.
As mentioned earlier, a moderate temperature increase (37°C to 42°C) was
observed in the bulk particle suspension while measuring SAR values in the presence of
magnetic field. To prove that the significant log-reduction of EC K99 is not due to
temperature increase alone, a CFU/ml assay on both the E. coli strains at elevated
temperature of 43°C was performed. The bacterial strains were incubated with PEOMNPs and GM3-MNPs for 120 minutes and this mixture was kept inside the holding
chamber of the AMF instrument by maintaining a constant temperature of 43°C for 120

98

minutes in the absence of magnetic field. No significant changes in CFU/ml of EC K99
and EC O157 were observed after exposing the bacteria to MNPs and at elevated
temperatures for 120 minutes. This strongly suggests that inactivation of the bacteria
cannot be attributed to temperature alone.

MagMED Inactivation of EC K99 and EC O157 in Mixed Culture
Pathogens interact with host in a heterogeneous environment; the efficacy of
utilizing MagMED for killing of the target bacteria EC K99 was evaluated in a mixedculture condition. Both strains of the E. coli cultures were mixed in the same container at
equal concentrations and added either the GM3-MNPs or the PEO-MNPs at a maximum
concentration of 650 µg Fe/ml. These mixtures underwent the same AMF exposure as
described earlier for 120 minutes and the CFU/ml reduction assay was done to determine
the inactivation rates of both strains of E. coli. As seen in Figure 7-A, a significant ~2.5log reduction (p<0.001) in CFU/ml of EC K99 in the presence of GM3-MNPs and AMF
exposure was observed. The other mixed culture containing PEO-MNPs did not show
significant difference in CFU/ml numbers compared to controls in the absence/presence
of AMF. In addition, ~1-log reduction (p<0.05) in CFU/ml of EC O157 was seen when
the mixed-cultures were added with PEO-MNPs or GM3-MNPs and underwent AMF
treatment for 120 minutes (Figure 7-B). This reduction in CFU/ml of EC O157 is
comparable in both mixed-culture and pure-culture experiments. Compared to CFU/ml
assay results of EC K99 in pure bacterial culture experiments where a ~3-log reduction
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was observed, the results obtained from mixed-culture experiments showed a ~2.5-log
reduction.

Figure 7. Colony Forming Unit (CFU) of E. coli strains in mixed-culture conditions
exposed to AMF for 120 minutes in the presence of MNPs (650 µg Fe/ml); A - CFU/ml of
EC K99 after AMF treatment; B - CFU/ml of EC O157 after AMF treatment. Data is
expressed as Mean ± SD (n=3); Statistical analysis - 2-Way Analysis of Variance
(ANOVA); * p-value <0.05, ** p-value <0.01, and *** p-value <0.001.
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This minor difference could be the result of a change in nanoparticle-to-bacterium
ratio in mixed-culture experiments. Since the nanoparticle-to-bacterium ratio was reduced
by half under mixed-culture settings, the probability of GM3-MNPs interacting with EC
K99 as well as EC O157 is also slightly reduced than in pure culture settings. To the best
of our knowledge, this is the first report wherein killing of targeted bacterial strains via
MagMED has been demonstrated in mixed-culture settings.

Investigating Interactions between GM3-MNPs and EC K99 via Transmission Electron
Microscopy (TEM)
One of the many causes for inactivation/killing of bacterial cells could be due to
physical damages of bacterial cell membrane that results from the presence of different
types of nanoparticles.85, 86 In order to investigate the bacterial-nanoparticle interactions
between GM3-MNPs and EC K99, TEM analysis on the samples was performed before
and after AMF exposure. Since the maximum reduction in CFU/ml of EC K99 was
achieved in the presence of 650 µg Fe/ml MNPs after 120 minutes, the same
experimental conditions to investigate if AMF exposure can exert any specific
morphological changes on the bacterial cell membrane of EC K99 was followed.
Visualizing TEM images, highly specific interactions taking place between GM3-MNPs
and outer membrane of EC K99 was observed. Figure 8-B shows the extent of GM3MNPs specifically attached to EC K99. The entire cell-surface of the bacteria was
covered with GM3-MNPs before applying AMF. There was no visible morphological
change seen on the bacterial cell surface of EC K99, which could also indicate that the
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nanoparticle system does not have an apparent inherent toxicity by itself towards
bacteria. Also, GM3-MNPs induced bacterial aggregation of EC K99 was clearly visible
in TEM images. In contrast, after applying AMF, the cell structure of EC K99 was seen
to be extremely damaged as seen in Figure 8-D.

Figure 8. TEM images of GM3-MNPs induced bacterial membrane damage of E. coli
strains: A, B, E, F - Before AMF, and C, D, G, H - after AMF treatment for 120 minutes.
Concentration of MNPs - 650 µg Fe/ml. Scale bar is 500 nm.

Please also note that the diameters of EC K99 were reduced to less than 0.5x0.25 µm
from the typical 1x0.5 µm. The nanoparticles were found internalized in cells of EC K99
after rupturing the cell membrane. Concurrent findings were also reported in a few
studies with regard to destruction of bacterial cell membrane via targeted photo-thermal
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lysis in the presence of nanoparticles.87, 88 Even after AMF exposure, GM3-MNPs were
found to remain attached onto bacterial cell debris, which suggests strong binding
interactions between GM3-MNPs and adhesin molecules of EC K99 present on the
bacterial cell surface. Interestingly, it was observed that both the polar ends of EC K99
were found to be much more deformed and broken. However, not much damage was seen
towards the horizontal length of EC K99. A large quantity of cell membrane debris was
observed in the TEM analysis suggesting that EC K99 would have undergone thermal
lysis after AMF exposure possibly due to highly localized temperature increase.
Moreover, both PEO-MNPs and GM3-MNPs did not show any substantial attachment to
EC O157 cells (Figure 8E to 8H). Even the cell membrane morphologies looked similar
to control group cells that were exposed to AMF without any MNPs. Thus, the TEM
analysis and CFU/ml assays support our initial findings regarding the specific
interactions occurring between GM3-MNPs and EC K99 and that GM3-MNPs found on
bacterial surface of EC K99 play an important role in lysing the bacterial cells
(bactericidal) when exposed to AMF.

Bacterial Live/Dead Fluorescence Assay
One of the common assays employed to check the membrane integrity of bacterial
cells is to use propidium iodide dye.89 Since the TEM analysis showed extensive
membrane damage of EC K99 cells after AMF treatment, to further support these results,
bacterial live/dead assays were performed. E. coli strains, after AMF exposure in the
presence of MNPs, were stained using mixture of SYTO 9 and propidium iodide dyes.
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SYTO 9 is a green-fluorescent dye that stains both live and dead bacterial cells by
entering inside them. Conversely, propidium iodide can only permeate those bacterial
cells whose cell membrane structures have been compromised and stains them red. For
this assay, the bacterial strains were mixed with different types of MNPs.

Figure 9. Live/Dead Staining Assay using SYTO 9 and Propidium iodide dyes. Both
strains EC K99 and EC O157 are stained with mixture containing the above-mentioned
dyes. The bacterial strains were initially mixed with PEO-MNPs and GM3-MNPs
(concentration - 650 µg Fe/ml) and then exposed to AMF treatment for 120 minutes. Live
bacterial cells appear green in color and dead cells appear red in color. All the images
are merged together for both green and red channel filters of the microscope. A, B, E,
and F represent E. coli cells incubated with MNPs but without AMF treatment. C, D, G,
and H represent E. coli cells incubated with MNPs in the presence of AMF.
Magnification - 400X, Scale bar - 100 µm.
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Figure 9 shows the results obtained after performing live/dead-staining assays. As
clearly seen in Figure 9-D, more than 95% of EC K99 cells were stained red in color after
exposure to AMF in the presence of GM3-MNPs. This proves that indeed EC K99 cells
experienced extensive cell membrane damage due to AMF. Also, ~50% of EC O157 cells
were stained red which suggests partial membrane damage (Figure 9G-9H). In contrast,
both E. coli strains stained green in color in the presence of MNPs but without exposure
to AMF (Figure 9 A, B, E, F). The control group of bacterial cells in the absence of both
MNPs and AMF also stained green in color. These results further support the non-toxic
nature of the nanoparticles. Several research groups obtained similar results for live/dead
staining assay when magnetic nanoparticles were used as antibacterial agents. 24, 82, 90
These results correlate with those obtained in CFU reduction assay wherein EC K99 and
EC O157 showed ~3-log reduction and ~1-log reduction in CFU/ml, respectively, after
120 minutes of AMF treatment in the presence of GM3-MNPs.

ATP Assay
The amount of ATP level present in any cell determines its metabolic state. In the
presence of toxic materials/chemicals, the metabolic state of the cell can change and the
intracellular ATP levels could drop because of toxicity. Higher levels of intracellular
ATP levels indicate that the cell is metabolically active and their levels directly correlate
to the actual number of bacterial cells present in the solution. Currently, several
antibiotics available in the market exert their effects on targeting bacterial membrane
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components to eradicate infections91, 92. To further demonstrate and explain the effect of
AMF exposure on the biochemical metabolism of the inner cell membrane, an ATP assay
based on luminescence was conducted to evaluate final ATP levels of EC K99 and EC
O157 after exposing them to AMF for 120 minutes in the presence of different types of
MNPs at their highest concentrations (650 µg Fe/ml).
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Figure 10. Intracellular ATP levels of bacterial strains in the presence of MNPs using
BacTiter Glo. A - ATP levels of EC K99 after 120 minutes of AMF treatment in the
presence of MNPs; B - ATP levels of EC O157 after 120 minutes of AMF treatment in the
presence of MNPs. Data expressed as Mean ± SD (n = 3); Statistical Analysis - 2-Way
Analysis of Variance (ANOVA). * p-value <0.05, ** p-value <0.01, and *** p-value
<0.001.
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As seen in Figure 10-A, a substantial decrease in intracellular ATP levels of EC
K99 (p<0.001) after 120 minutes of AMF treatment can be observed in the presence of
GM3-MNPs only while EC K99 in the presence of PEO-MNPs with/without AMF did
not show significant changes in ATP levels. In contrast, the intracellular levels of EC
O157 were found to be slightly reduced both in the presence of PEO-MNPs or GM3MNPs with AMF exposure (Figure 10-B). A similar decrease in ATP levels was reported
in P. aeruginosa when they were subjected to magnetic induction in the presence of ironoxide nanoparticles.24 One possible explanation for reduced ATP levels in the presence of
AMF exposure can be the decline in membrane potential of bacteria, which could lead to
interruption in ATP synthesis mechanisms (e.g., reduced proton motive force), membrane
depolarization and eventually cell-death.86, 93, 94
It is worth noting that EC O157 when treated with AMF in the presence of PEOMNPs or GM3-MNPs resulting in similar limited level of cell damage, reductions in
viable cells and intracellular ATPs. These results indicated that the changes are
independent of the GM3 functional groups present on the surface of MNPs. The
susceptibility of EC O157 to localized temperature changes due to proximity could be
due to a lower thermal decimal reduction time (D-value) of EC O157 than that of EC
K99.95

Conclusion
Proof-of-concept multi-anchored glycoconjugate GM3-MNPs that have high
affinity to adhesin of EC K99 were synthesized. The prepared nanoparticle system can
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specifically interact with adhesin molecules of EC K99 and cause agglutination through
nanoparticle-bacteria complex. Applying AMF treatment to such complex caused
significant reduction in viability of targeted bacteria EC K99 in both pure-culture and
mixed-cultures settings due to possible highly localized temperature increase. Exposure
to such conditions resulting in compromised membrane integrity of EC K99 as
determined through TEM imaging and Live/Dead staining. Moreover, GM3-MNPs
coupled with AMF resulted in significant decrease in the overall intra-cellular ATP levels
of the bacterium. Hence, the unique multi-anchored nanoparticle system in the presence
of AMF can be effectively used as novel non-antibiotic platform for local and selective
inactivation of the target bacteria in biological systems without affecting the viability of
nearby cells/tissues. In the event of gastro-intestinal (GI) tract infections caused by ETEC
pathogens, administered antibiotics can disrupt/destroy beneficial gut micro-flora in
addition to pathogens. It could cause various side effects in the human body along with
giving rise to antibiotic-resistant bacterial strains. The presented system can find useful
applications in treating such infections in animals and humans and in conditions when
administered antibiotics, especially those of the last-line-of-defense drugs, fail to
eradicate the infections due to drug-resistance. Future studies will involve optimization of
particle parameters including nanoparticle core-size and polymer coatings, as well as a
detailed investigation on the effects of field strength and frequency to maximize killing
rate of clinically relevant multi-drug resistant bacterial pathogens. Additionally,
biocompatibility of our nanoparticle system will be evaluated in human cell-lines and
small animal models.
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CHAPTER FOUR
HEPARIN FUNCTIONAL MAGNETITE FOR TREATMENT OF NEOINTIMAL
HYPERPLASIA
Contribution
This chapter is adapted from the article; In vitro studies of heparin-coated magnetic
nanoparticles for use in the treatment of neointimal hyperplasia, Nanomedicine:
Nanotechnology, Biology and Medicine, Benjamin D. Fellows, Nardine Ghobrial, Elliot
Mappus, Andrew Hargett, Mark Bolding, Delphine Dean, Olin Thompson Mefford,
Volume 14, Issue 4, 2018, Pages 1191-1200.1
My main contribution to this project was the synthetic design of the particles. This
includes the nanomaterial synthesis, surface chemistry and functionalization. I was also a
contributor in the discussion and interpretation of the results and the primary author on the
manuscript. I would like to extend a special acknowledgement to Nardine Ghobrial, Elliot
Mappus, Andrew Hargett, and Dr. Delphine Dean. They conducted the biological assays
to obtain the relevant cell data. Without them this research would not be possible. I would
also like to mention another collaborator, Dr. Mark Bolding, who was kind enough to do
animal model MRI with our materials.
Introduction
Currently cardiovascular disease (CVD) is the leading cause of mortality
worldwide where it accounts for approximately 30% of all deaths. 2 Cardiovascular disease
(CVD) continues to grow in prevalence and overall healthcare burden, coupled with an
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increasing elderly population within the United States, estimated total US healthcare cost
due to CVD is projected to exceed $1 trillion by 2030.3 Within CVD, atherosclerotic
cardiovascular disease (ACD) has become an epidemic that will only get worse with the
lowering of communicable disease related deaths, urbanization of third world countries and
the increasing longevity of the a populations lifespan. 4 In ACD, affected arteries are
occluded by a build-up of plaque within the vessel lumen. Over time, this limits blood flow,
potentially causing downstream problems such as heart attack, stroke, and in many cases
death. To prevent this resulting morbidity, many patients eventually require intervention to
remove or reduce the blockage. For such cases, percutaneous coronary intervention (PCI)
has become a standard procedure, utilizing stent and/or balloon angioplasty to increase
lumen diameters to satisfactory levels.5,

6

While highly effective in immediate

improvements to the lumen diameter, these procedures may suffer from complications,
particularly by restenosis. When stents are used, restenosis often occurs by neointimal
hyperplasia, an excessive proliferation of vascular smooth muscle cells within the vessel,
occluding the vessel once again.7-10
Current treatment options for neointimal hyperplasia focus on prevention, namely
by drug-eluting stents (DES).11, 12 This treatment has been largely effective in reducing
overall restenosis rates. DES reduced the incidence of in-stent restenosis (ISR) from 2040% with bare metal stents to 3-20% with DES.13 While DES have reduced the rate of
restenosis dramatically, they have introduced new complications such as late stent
thrombosis due to delayed endothelialization.14-17 Endothelial cells in the tunica intima act
as a selectively permeable barrier to prevent contact between VSMCs and growth factors
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circulating in the blood. Consequently, the endothelial layer inhibits intimal hyperplasia. 18
Most currently available DES use antiproliferative drugs such as paclitaxel and sirolimus,
which reduce the proliferation in both smooth muscle cells and endothelial cells, leading
to delayed endothelialization. DES also have limited control over drug payload, dosage, or
reloading.19, 20
For optimal performance, this therapy option should be effective in cases where
DESs fail and offer localized treatment without systemic effects. In addition to its widely
known anti-coagulation effects, heparin has been shown in literature to inhibit VSMC
proliferation after endothelial injury.21-26 It has also been shown to promote reendothelialization, which accelerates the healing process.21, 23, 24, 27 One treatment option
is systemically administering heparin. This treatment is associated with high rates of
bleeding and other vascular complications due to the activation of antithrombin III leading
to deactivation of thrombin and other proteases involved in blood clotting. 28, 29 Recent
advancements in magnetic targeting and magnetizable stents have shown the efficacy in
localization of the desired payload.30, 31 Adamo et al. have reported an approximate 36%
dose retention of magnetically labeled endothelial cells on a magnetized stent compared to
0.7% retention without a field present.32 Polyak et al. have also shown the effectiveness of
this magnetic cell therapy using magnetically labeled endothelial cells to prevent lumen
vessel narrowing.33 Other novel therapeutics have used this strategy to deliver high payload
percentages to stent areas, including delivery of vectors for gene therapy. 34 Herein, we
describe the synthesis and characterization of a combined magnetic targeting carrier system
paired with a pharmaceutical agent (heparin) to accomplish highly localized treatment

126

without full body circulation. The heparin-coated magnetite nanoparticles discussed in this
manuscript could utilize this mechanism deliver localized anti-coagulation and
antiproliferative effects at low concentrations effectively serving as a low toxicity targeted
therapeutic for neointimal hyperplasia.35

Experimental

Iron oxide nanoparticle synthesis
See chapter 3.

Polymer Synthesis
Poly (ethylene oxide), PEO synthesis: PEO was produced via previously reported
methods.36 Briefly, ethylene oxide (Praxair, >99%) was distilled into a high pressure Parr
reactor. Dry tetrahydrofuran (BDH, 99%) (THF) was injected along with a predetermined
amount of an anionic initiator, in this case potassium bistrimethyl silyl amide (Sigma
Aldrich, 0.5M in toluene). The reaction was allowed to run for 72 hours and was
subsequently terminated by opening the reactor to atmosphere. The synthesized PEO was
precipitated with diethyl ether (BDH, 99%) and washed (3x) by dispersing it in chloroform
(BDH, 99.8%), precipitating the polymer, centrifuging it and pouring off the residual
supernatant. The PEO was then dried under vacuum overnight. HNMR was performed to
calculate molecular weight as well as to confirm the presence of the protected amine
endgroup. Deprotection of the trimethyl silyl group was done in 1M hydrochloric acid
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(BDH, 37%) in methanol (BDH, 99.8%) and allowed to react for 4 hours. The polymer
methanol solution was diluted with water and the deprotected PEO was extracted (3x) with
chloroform from which it was precipitated with diethyl ether and dried under vacuum.
HNMR was performed to confirm the loss of the tri methyl silyl group.
Coupling of the PEO to the poly(acrylic acid) (Sigma Aldrich, 1,800 g/mol) was
done by dissolving both in dry THF (BDH, 99%) in a 5:1 ratio in the presence of a 1.1
molar excess of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (TCI, 98%) (EDC). The
solution was allowed to stir for 12 hours. The solution was filtered, further purified by
dissolution in chloroform following precipitation with diethyl ether (x3) and then dried
under vacuum. HNMR was done to confirm PAA-PEO coupling. Attachment of the anchor
group:

Dopamine

hydrochloride

(Sigma

Aldrich,

98%)

was

dissolved

in

dimethylformamide (Acros Organics, 99.8) (DMF) along with 1.1 excess triethylamine
(Fisher Scientific, 99%) and allowed to stir for 30 minutes. In a separate round bottom flask
the PEO-PAA was dissolved in DMF along with a 1.1 molar excess of EDC. To this the
dopamine hydrochloride solution was added and the combined solution was allowed to stir
for 12 hours. The solution was then filtered, purified by dissolution in chloroform then
precipitated in diethyl ether. The final product was dried under vacuum and analyzed via
HNMR to confirm the presence of the catechol.

Ligand exchange
See chapter 3.
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Modification of polymer coated iron oxide
Poly(ethylene oxide) (PEO) coated iron oxide nanoparticles (PCIO) were further
modified to have pendant primary amine groups for (3-dimethylaminopropyl)-N’ethylcarbodiimide hydrochloride (EDC) coupling of heparine instead of the hydroxyl
moieties present after ligand exchange. Particles were dispersed in dimethylformamide
(DMF), and reacted with an excess of 3-chloropropylamine (Sigma Aldrich, 98%) in the
presence of heavy excess triethylamine. Triethylamine was added to stay any adverse
effects from the resulting acid from the EDC salt. After 8 hours, the particles were
precipitated with diethylether, dispersed in water and run through a gel permeation
chromatography (GPC) column (BIO-RAD, Biogel P-100 gel) to purify off excess
reactants.
Iron oxide-heparin conjugation: Amine terminated polymer coated iron oxide
particles (NH2-PCIOs) were suspended in deionized (DI) water for heparin conjugation.
The molar amount of heparin (MP Biomedical, sodium salt low molecular weight) used in
the conjugation was approximately a 3:1 molar ratio of heparin to particle bound primary
amine. A 1.2 molar excess of both N-hydroxysulfosuccinimide (Thermo Scientific)
(sulfoNHS) and EDC were added to the aqueous heparin solution and allowed to stir for
30 minutes. The heparin-sulfoNHS complex was then combined with the particle solution
and left to react for 3-5 hours. Purification of excess heparin was done using GPC (BIORAD, Biogel P-100 gel). Samples of the eluent were collected after the particle band to
confirm separation of unbound heparin.
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Quantification of surface bound heparin
1,9-dimethylmethylene blue (DMMB) assays were used to quantify the amount of
heparin attached on the nanoparticles and confirm the success of heparin attachment. Using
a round-bottom 96 well plate, 180 µL of DMMB solution was added to 20 µL of sample.
Standard curves 0-100 µg/mL) of heparin and chondroitin sulfate (Sigma) were found to
not be significantly different. Samples were agitated for 5 seconds, and the absorbance at
530 nm was immediately read using a microplate reader. The coating of
heparin/nanoparticle was determined using the measured DMMB absorbance, the linear
regression equation, and the concentration of nanoparticle from the iron determination
assay.
Conjugated heparin and particles were purified from excess unbound heparin via
size exclusion chromatography. Visually the particles show up as a dark brown band on
the column. Fractions were taken to look at the heparin concentration vs. elution volume.
The initial spike which contained the particles shows a sharp increase and then decrease in
heparin followed by a sharp increase when the free heparin was eluted.

Dynamic light scattering and zeta potential
Dynamic light scattering (DLS) and zeta potential (ZP) were performed on a
Malvern Nano ZS zetasizer using a 633 nm laser. Both DLS and ZP were run using particle
samples suspended in DI water containing a small amount of electrolyte (NaCl). All
reported hydrodynamic diameters reflect the intensity weighted average.

130

The DLS determined hydrodynamic diameter shows an increase in the diameter
after modification with polymer to 150 nm. Not much change is seen with further
modification of heparin the end group or heparin. Heparin was determined to be attached
via DMMB analysis of the purified particles.

Transmission electron microscopy
To assess the cell uptake of the nanoparticles, transmission electron microscopy
(TEM) was used. Cells were cultured in standard incubation conditions using standard cell
culture media (CCM). Once the cells were 90% confluent, nanoparticles were added at a
concentration of 100 µg/mL diluted in CCM. After a 4-day incubation period, the cells
were trypsinized and centrifuged to form a pellet. The pellet was fixed with 3%
glutaraldehyde, osmified using 1% osmium tetroxide in water, dehydrated in a series of
ethanol, and then infiltrated and embedded in catalyzed medium grade LR White
embedding medium [Electron Microscopy Sciences/ 14380]. Ultrathin sections (70-90 nm)
were cut using a microtome and mounted on Formvar coated copper grids [Electron
Microscopy Sciences/FCF200-Cu]. A Hitachi Transmission Electron Microscope (TEM)
H7600 was used for imaging. Energy Dispersive X-Ray Analysis (EDAX) was used to
confirm the presence of iron inside the cells.
Particle characterization to show homogeneity and relative size using TEM.
Particles were expected to be unblocked due to the size of the core. This is important for
future application in magnetic targeting to magnetizable stents.
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Iron concentration assay
Iron concentrations were determined using a modified version of ASTM standard
E 394. A small sample of iron oxide particles was dissolved using approximately 200 µl of
concentrated HCl. The resulting solution is diluted to 10 ml and 5 stock solutions
containing 0.5, 1, 1.5, 2, and 2.5 ml of the original stock are made. Fe is reduced using
hydroxylamine hydrochloride (Alfa Aesar, 99%), complexed with 1,10-phenanthroline
(Sigma Aldrich, 99%), titrated via sodium acetate (Sigma Aldrich, 99%)-acetic acid
(Mallinckrodt Chemicals, 99.7%) solution, and finally diluted to 10ml. This phenanthroline
complex has high visible spectrum absorption and can be used to measure iron content by
creating a standard curve and comparing unknown sample absorbance to the standard
curve.

Vibrating sample magnetometry
Hysteresis loops of the iron oxide nanoparticles were done at the University of
South Carolina using a vibrating sample magnetometer (VSM) attachment on a Quantum
Designs physical property measurement system. The M vs. H loops were done at 300K
using a field sweeping ±15,000 Oe. The nanoparticle sample was dripped on a cotton qtip, fully dried, and placed under vacuum for measurement. The sample q-tip was digested
by heating to 600 °C and the remaining iron was assayed. Subtraction of the paramagnetic
of the q tip was done in post processing of the data.
Magnetization curve showing the superparamagnetic character of the heparin
loaded nanoparticles at room 300 Kelvin. Saturation magnetization is in the expected range
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for magnetite. This also illustrates the oxidative stability after being transferred into
aqueous solution as we do not see a drop in expected magnetic properties.

Magnetic resonance imaging
All animal procedures were approved by the Institutional Animal Care and Use
Committee of University of Alabama Birmingham (UAB) and adhered to the experimental
animal care guidelines. Female athymic nude mice, 6-8 weeks of age were obtained from
Charles River Breeding Laboratories and maintained under controlled conditions (25 °C,
65% humid, and 12 h light/dark cycle) at the UAB animal facility. Mice were anesthetized
with isoflurane (2-3%) and placed in a custom-made mouse bed equipped with an
anesthesia nose cone and a water bath circulation system to maintain the animal’s body
temperature during imaging. A pneumatic pillow sensor was placed under the mouse’s
chest and connected through an ERT Control/Gating Module (SA Instruments) to acquire
the mouse’s respiratory cycle. The animal was then positioned inside the bore of a 9.4T
Bruker BioSpec scanner (Bruker BioSpin, Billerica, MA) and MR imaged with a custom
volume coil. T1- and T2- weighted images were collected with the following parameters:
coronal slices, slice thickness 1.5 mm, voxel size of 0.2x0.2x1.5 mm voxels, 0.5 mm gap,
FOV = 85×35 mm.

In vitro studies
Control conditions were created using untreated cells, heparin of molecular weight
3,000 g/mol solutions, and amine terminated nanoparticles (NP-NH2). Experimental
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conditions were evaluated for rat vascular smooth muscle cells (VSMCs), porcine
endothelial cells (PECs), and rat 3T3 fibroblasts (3T3s) between passages 4-9 and 70-90%
confluence. All cell culture media, including control media, experimental media, and
heparin solution solvent, was created as complete cell media (CCM) containing High
Glucose Dulbecco’s Modified Eagle’s Medium, 10% fetal bovine serum, and 1%
penicillin/streptomycin. All incubation conditions were conducted at 37oC and 5% CO2.
For experimental conditions, both sets of nanoparticles were used in concentrations of 1,
10, 25, 50, and 100 ug/mL. Heparin-coated nanoparticles used in the in vitro studies were
found to average 2.956 ug heparin per ug nanoparticle. Heparin solutions in CCM were
used in concentrations of 1.56, 6.25, 25, 100, 400, and 1600 ug/mL.

Cell proliferation and metabolism
Cell proliferation and metabolic activity were assessed using the CellTiter 96®
Aqueous One Solution Cell Proliferation Assay MTS kit by Promega. This kit uses a onestep colorimetric method to quantify viable cells. These viable cells reduce the MTS
tetrazolium compound into a colored formazan product. Cells were seeded at 2,000
cells/well in CCM into a 96-well plate and incubated for 24 hours. Experimental conditions
consisting of the full spectrum of nanoparticles, heparin solutions, and controls were
applied and incubated for 48 hours. Following experimental conditions, cells were further
incubated for 2 hours in a 1:5 volume ratio of MTS Assay kit and CCM. Absorbance was
read at 490 nm using a microplate reader normalized against cell-free plates containing
only CCM and MTS to compensate for any color distortion caused by media.
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Live/dead assay
For this assay, cells were seeded at 20,000 cells/well into a 24-well plate and
allowed 72 hours to adhere and grow in the standard CCM. Following this 72-hour
incubation period, cells were checked to confirm confluence. For control conditions and
analysis, control wells without nanoparticles were incubated in fresh CCM. Cells were then
incubated under standard incubation conditions for a further 48 hours. The Live/Dead
Assay Viability/Cytotoxicity kit (Life Technologies) was used to create solutions of 2 μM
calcein acetoxymethyl (2 μM C), 4 μM ethidium homodimer-1 (4 μM Etd-1), and 2 μM
calcein acetoxymethyl with 4 μM ethdium homodimer-1 (2,4 μM C+Etd-1) solutions
diluted in phosphate-buffered saline (PBS) and protected from light. All experimental
conditions were treated with 2,4 μM C+Etd-1 solution. Positive controls were treated with
all three solutions and negative controls, created with 70% ethanol, were treated with 2 μM
C and 4 μM Etd-1 solutions. All treated cells were incubated with live/dead assay kit
solutions for 30 minutes and imaged using an EVOS fluorescent microscope for red/green
fluorescence. This was additionally quantified using a microplate reader for fluorescence
from 485 nm excitation to 530 nm emission and 530 nm excitation to 645nm emission.

Immunofluorescence staining
Cells were seeded at 2,000 cells/well into a 96 well plate and allowed to grow for
24 hours in CCM. This media was then replaced for experimental conditions. Control
groups consisted of cells in CCM. Cells were incubated in experimental conditions for 48
hours and then fixed with 4% paraformaldehyde (Sigma Aldrich). VSMCs were targeted
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for smooth muscle actin using Rabbit Polyclonal Primary Antibody to Alpha Smooth
Muscle Actin (Abcam) paired with Secondary Antibody Donkey Anti-Rabbit (Abcam) to
yield a green fluorescence for actin fibers. Endothelial cells were targeted for VE-Cadherin
using Mouse Monoclonal Primary Antibody to VE-Cadherin (Santa Cruz Biotechnology)
paired with Secondary Antibody Donkey Anti-Mouse (Abcam) to yield a red fluorescence
on cellular junctions. 3T3 fibroblasts were targeted for collagen type I using Mouse
Monoclonal Primary Antibody to Collagen Type I (Abcam) paired with Secondary
Antibody Donkey Anti-Mouse (Abcam) to yield a green fluorescence on collagen. All cell
types were further stained with (4’,6-diamidino-2-phenylindole) (DAPI) for cell nucleus.
Following stain, cells were imaged using an EVOS FL Imaging System.

Statistical analysis
A 2-tailed student t test was used to preform statistical analysis. P values of < 0.05
are considered statistically significant.

Results and Discussion
There are a multitude of ways in literature that are used to synthesize magnetic
nanoparticles with two of the most popular techniques being coprecipitation of iron salts
and thermal decomposition of iron containing organometallics. 37 For this study particles
synthesized via a thermal decomposition method were used as core size and morphology
are controllable and samples have a low size dispersion.38 Because of this, magnetic
parameters can be controlled to a high degree due to low core size variation. The particles
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as synthesized however are hydrophobic due to the stabilizing oleic acid ligands used in
the high temperature synthesis. To remedy this, many groups have done work and used
ligand exchange to confer stability in aqueous media.39-41 In this case a PEG-PAAdopamine polymer complex was used for the ligand with PEG being the bio-inert
stabilizing ligand and the catechol being the iron-binding moiety seen in figure 1.

Figure 1. Representative image of the heparin particle system and surface chemistry used
for functionalization.

Dynamic light scattering (DLS) and zeta-potential studies were done on the
particles before and after modification to ensure stability and investigate final
hydrodynamic diameter of the particles in DI water.
Iron oxide core diameters were found to be approximately 24.3 ± 1.9 nm by
transmission electron microscopy (TEM) via size analysis using Image J. This places the
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particles firmly in the superparamagnetic regime, which was confirmed by the vibrating
sample magnetometry showing no remnant magnetization and a saturation magnetization
of approximately 62 emu/g Fe at 300 K. This is comparable to the particles used by Vosen
et al. who showed particles with saturation magnetization of 62 emu/g and 92 emu/g could
be used for magnetic targeting.34 It is also much greater than the particles used (~10 emu/g
particles) for successful endothelial capture by Polyak et al. who also talk extensively about
the stent magnetics and states that even far away from the gradient source the particles are
magnetically saturated in vivo.35 The size also indicates that issues with rapid renal
clearance will not be encountered. The magnetic characteristics are important; as the
particles will be used for magnetic adherence to magnetizable stents in future work. 35, 42, 43
The use of poly(ethylene glycol) (PEG) as a stabilizing ligand has been heavily
used in biomedical applications, as it confers a high degree of particle stability in aqueous
environments, renders the attached moiety/particle bioinert, and does not interact with the
large amount of proteins and salts in bodily fluids. In this case a 5,000 g/mol molecular
weight PEG brush was used lending more than enough steric interaction between particles
confer stability in aqueous environments.41 Moreover, disassociation of the polymer brush
from the particle surface is unlikely as the binding moiety to the particle consists of
multiple catechols which have an enormous affinity for iron oxides.44 To create primary
amine groups on the particle surface for EDC chemistry the polymer coated particles were
reacted with chloropropylamine. Heparin loading of the particles was done using simple
EDC sulfoNHS chemistry with the purification of unbound heparin being done by size
exclusion chromatography (SEC) which is shown in figure 2.
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Figure 2. DMMB assay on elution fractions from aqueous GPC purification of particle
bound heparin and free heparin. Initial spike between 10 and 50 minutes corresponds to
the particles which were seen in the column as a dark brown band.

The initial peak corresponds to visual elution of the heparin coated iron oxide
particles, which were seen as a dark black/brown band in the column. The particle fraction
collected was then tested via dimethylmethylene blue Assay (DMMB) and concentration
was calculated to assess heparin loading per µg of iron.
The proliferative properties of the functionalized nanoparticles (amine and heparin)
were investigated using three relevant cell lines in conjunction with both cell culture media
as a negative control and raw heparin solution as a positive control. Cell viability and
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proliferation were compared to the negative control. The three cell lines of interest included
vascular smooth muscle cells (VSMCs), 3T3 fibroblasts, and porcine endothelial cells.
These lines were chosen for their role in neointimal hyperplasia. MTS and live/dead assays
were used to evaluate cell viability and proliferation. Comparisons between MTS and
live/dead assays were used to determine if the reduction in cell counts were due to cell
death or suppression of proliferation. Immunofluorescence staining of alpha smooth
muscle actin fibers was used to indicate phenotype changes in the vascular smooth muscle
cells.
VSMCs were treated with varying concentrations of both heparin loaded and
unloaded amine terminated particles varying from 0-100 µg Fe/ml. MTS assay done on
amine terminated particles showed some amount of cell death at all concentrations (figure
3 B). Heparin coated particles showed an increasing inhibition of VSMC cell proliferation
starting at 1 µg Fe/ml (p-value = 0.0007) with an increasing inhibitory effect up to 100 µg
Fe/ml (p-value = 0.0006) where effects measured by the MTS assay were indistinguishable
from the amine coated particles (figure 3 A).
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Figure 3. MTS assay of 3 cell lines commonly associated with neointimal hyperplasia
incubated with A) heparin coated nanoparticles, B) primary amine terminal nanoparticles,
C) pure heparin.

141

It is important to note that MTS proliferation assays were done using particles with
a heparin loading of 0.976 µg of heparin/µg Fe. Live/dead assays (figure 3) were also
performed as a secondary indication of cell viability. Amine terminated particles showed a
significant decrease in cell viability at particle concentrations of 25 µg Fe/ml (figure 3B)
where the heparin coated particles showed a significant reduction in cell viability at 10 µg
Fe/ml (figure 3A). Although initially MTS and live/dead assay results for the heparin
loaded particles are not seemingly in agreement it is again important to note that the
live/dead assays were done using a different batch of synthesized particles with a much
higher loading of heparin (2.89 µg heparin/µg Fe). Both assays indicate however that
heparin concentrations above 10 µg lead to significantly lowered cell viability. Live/dead
assays done on the heparin coated particles showed that the reduction seen in the MTS
assay was due to suppression in proliferation and not cell death. Comparatively both MTS
and Live dead assays on VSMCs incubated with up to 3200 µg/ml of heparin showed no
effects on the resulting cell viability as seen in figure 3 C and figure 4 C. Although reports
of as little as 25 µg heparin/ml inhibiting the proliferation of VSMCs exist, it is important
to note that all low molecular weight heparin does not show the same chemical, physical
and biological properties.45, 46 This may be due to the different starting source materials
and chemical processing (depolymerization).46 The pure heparin experiments in this
manuscript were done using the same heparin used in the particle conjugation as to avoid
erroneous results due to the variance in low molecular weight heparin from different
manufacturers.

142

Figure 4. Live/dead assay of 3 cell lines commonly associated with neointimal hyperplasia
incubated with A) heparin coated nanoparticles, B) primary amine terminal nanoparticles,
C) pure heparin.
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Immunofluorescence imaging was used to observe VSMC morphology and visual
trends in marker expression for each cell line. Figure 5 shows one sample image from each
culture condition. Cell number was quantified over several images in the culture and
compared to the MTS data and the trends were similar. Immunofluorescence staining of
alpha smooth muscle actin (figure 5) was used to indicate the VSMCs lineage towards the
synthetic or contractile phenotype. VSMCs in their synthetic phenotype typically exhibit a
rhomboid shape with randomly oriented fibers. When in the contractile phenotype VSMCs
have a spindle shape with contractile apparatuses aligned into organized fibers. 47
Incubation with amine functional particles in concentration of both 1 and 10 µg Fe/ml
showed disruption of normal cell behavior resulting in cell fragmentation. It is interesting
that the nuclei have seemingly been removed/destroyed, as it is not seen in the stained
samples. VSMCs incubated with heparin-coated particles at both concentrations of 1 and
25 µg Fe/ml exhibited preference towards the contractile phenotype as shown by the
organized actin distribution and spindle shape associated with the quiescent state.
Immunofluorescence staining of the PECs and fibroblasts showed no change in expression
of VE-cadherin or collagen I.
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Figure 5. Immunofluorescence staining of relevant cell lines to observe phenotypic
changes. Top row shows VSMCs. Smooth muscle actin is seen in green and nuclei are seen
in blue. In the middle row endothelial cells are shown with VE-cadherin in cellular
junctions. 3T3 fibroblasts were stained for collagen I.

Endothelial cells play a vital role in the formation of the tunica intima and it is
important to observe effects due to interaction with the particles as proper
endothelialization is needed for proper healing.18, 21 MTS and live/dead assays were run on
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porcine endothelial cells incubated with the same varying concentration of both the amine
terminated particles and the heparin coated particles. MTS on endothelial cells incubated
with the amine terminated particles (figure 3 B) showed a pattern of increased proliferation
leading to an increase in viability with a sudden drop to zero at 50 µg Fe/ml (p-value <
0.0001). The MTS after incubation with heparin coated particles showed the same trend of
increased cell viability due to an increase in proliferation up through the 100 µg Fe/ml (pvalue = 0.0083), which was the highest concentration of particles used in this study (figure
3 A). The same increase in viability was also seen with raw heparin at concentrations
between 1.56 and 1600 µg/ml (figure 3 C). Live/dead assays conducted using amine
terminated particles showed relatively stable cell viability between 90% and 120% until a
major drop to 0% is seen at 50 µg Fe/ml (figure 4 B). This is consistent with the MTS assay
and shows that at concentrations above 50 µg Fe/ml the amine terminated particles induce
cell death and nonproliferation. Live/dead assays of the endothelial cells incubated with
the heparin coated particles showed a lowering of the cell viability from 100% to
approximately 60% at 10 µg Fe/ml, with higher concentrations of particles (up to 100 µg
Fe/ml) maintaining the 60% cell viability seen at 10 µg Fe/ml (figure 4 A). Live/dead
assays after incubation with pure heparin showed no discernable trend in cell viability up
to 1600 µg/ml (figure 4 C).
MTS and live/dead assays were also performed on 3T3 mouse fibroblasts.
Fibroblasts take a passive role in the healing of intimal hyperplasia so relative lack of
response to the administered treatment is preferential. 48 MTS of fibroblast cells treated with
amine terminated particles showed relatively stable cell viability between 80-100% up to
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25 µg Fe/ml (p-value = 0.0002) where cell viability sharply drops to 15% and further to
0% at 50 µg Fe/ml (p-value = 0.0002) and 100 µg Fe/ml (p-value = 0.0002) (figure 3 B).
Fibroblasts treated with heparin coated particles show a relatively stable cell viability
throughout incubation with all particle concentrations with no discernable trend in viability
(figure 3 A). The cell viability of fibroblasts incubated with pure heparin up to 1600 µg/ml
show slightly erratic behavior with no real trend (figure 3 C). Live/dead assays done on
fibroblasts incubated with amine terminated particles confirms the behavior seen in the
MTS assay although the viability seen from live/dead immediately drops to approximately
50% at incubation with only 1 µg Fe/ml and drops further to 0% with 25 µg Fe/ml up to
100 µg Fe/ml (figure 4 B). Live/dead assays done using heparin coated particles agreed
with the MTS assay done as no discernable trend was seen. A slight decrease in cell
viability to 50% was seen at both 10 µg Fe/ml and 25 µg Fe/ml but at concentrations above
25 µg Fe/ml cell viability was back above 80% (figure 4 A). Live/dead assays done on
fibroblasts incubated with only heparin showed a slight decreasing trend from 100%
viability to approximately 65 percent viability at the highest concentration of heparin used
(1600 µg/ml) (figure 4C).
Magnetite nanoparticle uptake by the cells was observed using TEM (figure 6).
Excess particles were washed before fixation to get rid of any particles that were not up
taken by the cells. After embedding the cells, they were sectioned into 70-90 nm thick
sections. The images show a cross-section inside the cells. As observed in the images,
particles were found mainly in the cytoplasm of the cells either individually or clustered in
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endosomes. The images also suggest that the particles are likely internalized by the cell
through pinocytosis (figure 5 B arrow).

Figure 6. A) TEM image (scale bar = 2 µm) of rat vascular fibroblasts treated with
magnetite nanoparticles. Nanoparticles internalized in endosomes. B) TEM image (scale
bar = 500nm). C) EDX of cells showing appearance if iron peaks at 6.4 and 7.1 KeV
(circled in red).

The presence of iron was assessed using Energy Dispersive X-Ray Analysis
(EDAX) microanalysis system; data shown in figure 6C. A large Fe peak was seen in the
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cellular sample indicating uptake of the particles into the cell and not simple attachment to
the outer cellular membrane.
Three female athymic nude mice were in injected IV with 100 µl of approximately
250 µg Fe/ml in buffer. Mice were MR imaged at 9.4T pre-injection, 20 min post injection
and 1.5 hours later. T1- and T2- weighted images were collected. No physiological
reactions to the injection were observed acutely in the three imaged animals. No adverse
reactions were observed post injection in the animal that was sacrificed one week later. No
significant changes were observed in the T1-weighted images. T2-weigted images showed
significant hyperintensity (signal decrease) 20 min post injection in highly vascularized
regions including the kidneys, brain, and heart (Table 1). This was expected with the
particles as magnetite is used as a T2 contrast agent. The hyperintesity signal intensity
reported in table 1 was calculated from the specific regions of interest shown in figure 7.

Table 1. Mean intensity of ROIs in arbitrary units pre- and 20 min post injection. ROIs
were circular with a radius of 1.8 mm. ROIs 1 and 3 were in the kidneys and ROI 2 was
in the brain.

Pre

Post

ROI

Mean

SD

Mean

SD

1
2
3

8085
1994
8177

604
254
603

5535
737
4277

798
189
719
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Figure 7. T2-weighted MR images of mouse injected IV with 100 µl of 200 µg Fe/ml in
buffer. (a) pre-injection. (b) 20 min post injection.

Image intensities returned to baseline at 1.5 hours. Although not a quantitative
indication of high circulation times, MRI results suggest that the heparin loaded particles
are in circulation and cleared after 1.5 hrs. This shows that unlike conventional heparin
which binds heavily to cell surfaces, the particles maintain circulation instead of being
immobilized at the injection site. This is promising as it may allow intravenous
administration of the heparin coated particles without high amounts of rapid unwanted
binding to cellular sites.
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Although encouraging, further studies are needed to construct a more accurate and
validated pharmacokinetic profile of the heparin coated nanoparticles. This should include
fluorescent tagging of the particles and ICP-OES of major organs, blood and excrement to
look at iron content and circulating nanoparticle concentration at varying time points after
administration. This can be correlated with the hyperintensity MR signal to construct a
more complete understanding of the in vivo behavior.
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Fe Radio labeled Fe3O4 or

13

C

labeled PEG could also be used to validate and further confirm the biodistribution,
retention, and excretion of the nanomaterial.49

Conclusions
Heparin, both administered locally and systemically, has been used for years as an
anticoagulant. Studies have shown that heparin has antiproliferation properties but it has
not been used clinically due to the large dosage needed as heparin is cleared quickly invivo. Results in this manuscript show that magnetic nanoparticles coated in heparin can
achieve the antiproliferative activity of bulk heparin at much lower doses, in part due to
the large surface area to volume ratio of the particles leading to high heparin/particle
loading. Restriction on the proliferation of vascular smooth muscle cells due to phenotypic
changes was seen with concentrations of heparin coated particles as low as 1 µg of Fe/ml.
Heparin coated particles were shown to have a proliferative effect on endothelial cells.
While pure heparin also induces proliferation in endothelial cells, comparative heparin
concentrations to achieve this were much lower with the heparin coated particles.
Fibroblast cells showed a relative lack of response to the heparin coated particles.
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Anticoagulative properties of the heparin loaded nanoparticles will be investigated in future
work to further characterize the potential effect on thrombi formation. Biodistribution via
MRI showed relatively long circulation times in-vivo which is desirable for treatment of
neointimal hyperplasia. Long circulation times are also paramount for possible use in
magnetically targeted therapy using magnetically stents, as multiple passes through the
stented area would increase the probability of magnetically attracting a heparin loaded
particle to the stent, localizing the treatment to the stent area.
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CHAPTER FIVE
COMBINATION T1 AND T2 CONTRAST AGENTS FOR DUAL MODE MAGNETIC
RESONANCE IMAGING.
Introduction
One of the largest fields where magnetic materials see usage is that of MRI
contrast agents. Typically small molecule paramagnetic chelates will be employed as T1
shortening agents.1 Because these molecules diffuse rapidly and change the positive
contrast signal they are widely employed in the medical field to detect lesions etc. where
multiple environments may have a similar Larmor frequency and therefore are
indistinguishable from each other in a non-contrast enhanced scan. 2 These mainly consist
of gadolinium complexed with either linear ethylenediaminetetraacetic acid (EDTA)
derivatives, or macrocyclic molecules such as 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7,
10-tetraacetic acid (DOTA), 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7-triacetic acid
(DO3A), and their functional derivatives.1 Although toxic, gadolinium is a prime
candidate for T1 contrast enhancement as it has a high magnetic moment due to its seven
unpaired f electrons and a relatively long electronic relaxation time.3 The toxicity can
also be significantly reduced by using the macrocyclic class of chelates vs the linear, as
they have lower muscular deposition and are generally regarded as safer. 4
Magnetic nanoparticles, typically magnetite, are also used as contrast agents for
MRI. However as was alluded to in the introductory chapter, the relaxation mechanism
that they primarily affect is much different. Because the magnetic particles produce large
inhomogeneities in the local field, they primarily effect the local field felt by the
surrounding protons which massively changes the velocity of dephasing. 5 Because of this
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magnetic nanoparticles are thought of as T2 contrast agents. Although the magnitude of
the change in T2 seen from particles is typically an order of magnitude greater than the
change imparted on T1 by gadolinium, they are not favored by clinicians as they impart a
negative contrast change, there are difficulties in biological half-life, and questionable
side effects have been seen in some patients.6
Each individual agent, either the Gd based chelates or magnetic nanoparticles, is
useful when only a single mode of imaging is used. However, there is an inherent issue
when using only T1 or T2 weighted imaging procedures. Each of the specific modalities
can be heavily influenced by artifacts that show up in final scan images. These artifacts
typically manifest from in vivo phenomena such as calcification, clotting, fats, air, etc.
and they may mimic the behavior of single mode contrast agents, or cause severe
misrepresentation of the issue.7 These can be very problematic as they may lead to poor
diagnostic accuracy, extended imaging procedures, and costly secondary scans including
more scans with contrast. Shin et al. propose an interesting concept to eliminate the
possibility of misinterpreting MR artifacts as administered contrast. 8 They proposed that
it is possible to use an AND gate after taking both T1 and T2 weighted images to
eliminate artifacts seen on either of the single weighted image.8
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Figure1. Proposed dual mode contrast agent using coupled T1 and T2 agents. The *
indicates that part of the figure was adapted from, Shin, T. H.; Choi, J. S.; Yun, S.; Kim,
I. S.; Song, H. T.; Kim, Y.; Park, K. I.; Cheon, J. T-1 and T-2 Dual-Mode MRI Contrast
Agent for Enhancing Accuracy by Engineered Nanomaterials. Acs Nano 2014, 8, 33933401.

To do this however the contrast agent must fulfill multiple criteria that today’s
clinically available agents do not satisfy. This includes a high relaxivity for both modes,
as well as a relaxivity ratio that is small so T2 shortening does not detrimentally effect the
T1 imaging process.9 By combining the shortening and relaxation effects of both
magnetite nanoparticles and gadolinium chelates it may be possible to increase overall R1
relaxivity while conversely lowering the extremely high R2 from the magnetite
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nanoparticle.10 The proposed dual mode contrast agent is represented in figure 1. This is
one of the strategy’s outlined by Zhou et al. to create a dual mode contrast agent via inner
and outer water shell management.11 This research looks at the relaxivity effects on water
different size magnetite particles functionalized with gadolinium chelates using varying
molecular weight poly(ethylene glycol) polymers as spacers. By systematically looking at
different size cores and spacer lengths it is possible to elucidate the effects of the
gadolinium functionalization and their effect on the R2/R1 ratio.
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Experimental
Synthesis of PEO-PAA-Dopamine

Figure 2. Synthesis of multianchored alkyne functional polymer. 1) ring opening of
ethylene oxide to for protected amine terminated poly(ethylene glycol) (PEG). 2)
Alkylation of alcohol for alkyne functionality. 3) Deprotection of amine. 4+5) EDC
chemistry to attach PEG and dopamine to poly(acrylic acid) backbone.

PEO synthesis: Ethylene oxide was distilled into a high pressure Parr reactor. Dry
THF was injected along with a predetermined amount of an anionic initiatior (in this case
potassium bistrimethyl silyl amide). The reaction was allowed to run for 72 hours and
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was subsequently terminated by opening the reactor to atmosphere. The synthesized PEO
was precipitated with diethyl ether and washed (3x) by dispersing it in chloroform,
precipitating the polymer, centrifuging it and pouring off the residual supernatant. The
PEO was then dried under vacuum overnight. HNMR was performed to calculate
molecular weight as well as to confirm the presence of the protected amine endgroup.
Under dry N2 atmosphere heterofunctional PEO and sodium hydride (in slight excess)
were dissolved in dry THF. This was allowed to react for 30 minutes before an excess of
propargyl bromide was added dropwise to the solution over 15 minutes. Once all of the
propargyl bromide was added, the solution was allowed to stir for 12 hours at room
temperature. The polymer was then purified by dissolution in chloroform and
precipitation with diethyl ether (x3) and dried under vacuum for 12 hours. HNMR was
performed to confirm the presence of an alkyne.
Deprotection of the trimethyl silyl group was done in 1M Hydrochloric acid in
methanol and allowed to react for 4 hours. The polymer methanol solution was diluted
with water and the deprotected PEO was extracted (3x) with chloroform from which it
was precipitated with diethyl ether and dried under vacuum. HNMR was performed to
confirm the loss of the tri methyl silyl group.
Coupling of the PEO to the poly(acrylic acid) was done by dissolving both in dry
DMF in a 5:1 ratio. To this 1.1 excess EDC as well as catalytic amounts of DMAP were
added. The solution was allowed to stir for 12 hours. The solution was filtered, further
purified by dissolution in chloroform following precipitation with diethyl ether (x3) and
then dried under vacuum. HNMR was done to confirm PAA-PEO coupling.
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Attachment of the anchor group: Dopamine hydrochloride was dissolved in THY along
with 1.1 excess triethylamine and allowed to stir for 30 minutes. In a separate roundbottom the PEO-PAA was dissolved in THF along with EDC and catalytic amounts of
DMAP. To this the dopamine hydrochloride solution was added and the combined
solution was allowed to stir for 12 hours. The solution was then filtered, purified by
dissolution in chloroform then precipitated in diethyl ether. The final product was dried
under vacuum and analyzed via HNMR (Figure 3) and IR to confirm the presence of the
catechol.
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Figure 3. Representative HNMR of final polymer after full modification m-multiplet, qquartet, t-triplet, b-broad. 0 ppm = tms, (m) 0.75-1.5 ppm = PAA, (q) 2.42 ppm and (t)
4.18 ppm = alkyne, (b) 2.8 ppm = alcohol, (b,m) 3.62 ppm = PEG.

Synthesis of magnetite nanoparticles
Magnetite nanoparticles were synthesized via thermal decomposition of on
organometallic precursor in a high boiling point organic solvent. Iron (III)
acetylacetonate (1.074 g) was combined in a 3 neck round bottom with varying amounts
of oleic acid and octadecene depending on the desired particle size. The vessel was
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initially purged with N2 after which flow was adjusted to 0.1 L/min ensuring an inert
environment. The vessel was then heated to 350 °C and left to react for 3 hours. At 3
hours the reaction was quenched by removing from heat, and left to cool under inert
atmosphere. The resulting particles were dispersed in minimal hexanes and precipitated
using a mixture of 3:1 ethanol to acetone (x3). Particles were dispersed in toluene and run
through an organic based GPC column to further remove excess ligand. TEM and size
analysis was then done on the particles to ensure size specificity.

Figure 4. Particles of four different sizes used for the gadolinium functionalization
ranging from 14.9nm to 34.3nm.

Synthesis of clickable chelate
Azido-DOTA complex was synthesized in accordance with Szíjjártó et al. 12 2azidoethanol and triethylamine were dissolved in dichloromethane (DCM) under an inert
N2 atmosphere. The solution was cooled in an ice bath and methanesulfonyl chloride was
added dropwise via syringe. The reaction was stirred for two hours. After two hours
dilute HCL aq. was added to solution. The phases were separated and the aqueous phase
was extracted once with fresh DCM. The organic phases were combined and dried with
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MgSO4. Evaporation of the solvent afforded an oily yellow liquid final product of
mesylated azidoethanol.
Mesylated azidoethanol was added dropwise to a suspension of excess cyclen in
chloroform. The solution was stirred for 24 hours at room temperature and allowed to
react. The reaction was then concentrated and purified via a gradient flash
chromatography (0 %-15 % DCM in methanol then 10:10:1-5:5:1 DCM-MeOH-saturated
aq. NH3. Final monoalkylated cyclen product was a pale yellow oil and was verified via
HNMR.
Monoalkylated cyclen and Na2CO3 were suspended in acetonitrile (ACN). Tertbutyl bromoacetate was added to the reaction and the mixture was heated to 70°C for 24
hours. The mixture was filtered, concentrated and purified via flash column. The final
product was a pale yellow oil which was verified by HNMR.
Deprotection of the tert-butyl groups was done in a 1:1 solution of triflouro acetic
acid and dichloromethane by stirring at room temperature for 24 hours. The volatile
byproduct and solvent was evaporated off and the resulting product was dried for 48
hours in a vacuum oven at ambient temperature. The final product was a sticky yellow
liquid and was verified via HNMR and IR for the correct functional groups.
Chelation of the gadolinium was performed in methanol my mixing a 1:1.05
equivalent of the chelate to GdCl3. The mixture was heated to 45 °C for 24 hours. The
mixture was then poured into diethyl ether and the precipitate was collected. The
precipitate was once more dissolved in MeOH and precipitated for purification. The solid
precipitate was dried under vacuum for 48 hours prior to analysis via FTIR (figure 5).
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Figure 5. FTIR of azide functional DO3A based gadolinium chelate used to functionalize
magnetic particles.

Ligand exchange
Both magnetite nanoparticles as well as the PEO-PAA-dopamine were suspended
separately in 5ml of chloroform. The particles at an approximate concentration of 3
mg/ml of Fe and the polymer at approximately 40 mg/ml. The polymer was then
transferred to a scintillation vial capped with a septum and placed in a sonication bath.
The bath was turned on and over the course of 15 minutes the magnetic nanoparticle
solution was injected into the polymer solution. Once injection was finished, the
combined solution was allowed to further sonicate for 15 minutes. The solution was then
removed and put on a shaker table for 72 hours. The chloroform was then removed via
rotary evaporator and further dried under vacuum. DI H 2O was then added and the vile
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was sonicated to help mediate dissolution into the water. The water based particles were
then filtered through a 0.2 micron nylon filter to ensure large aggregates were not present.
The solutions were then run through a GPC column to separate excess polymer from the
water suspendable particles. Further purification was done using both centrifugation and
rare earth magnets to pull particles out of solution, decant the supernatant, and redisperse
in DI H2O.

THPTA synthesis adapted from Hong et al.13
Synthesis of bis-triphenylphosphine complex of Cu(I)acetate:
Cu(I)acetate (1 g) and triphenylphosphine (4.3 g) were combined in a round bottom flask
and purged with dry N2. 50 ml of dry dichloromethane was added to dissolve the reagents
and the reaction was allowed to stir for 1 hour. The contents were hen filtered over cellite
and the resulting colorless solution was immediately poured into 500ml of ethyl ether and
put in the freezer for 12 hours to crystalize. The product was then filtered and dried under
vacuum.
Synthesis of 3-azido-1-propanol:
3-bromo-1-propanol (20 g) and sodium azide (18.7 g) were dissolved in DI H 2O and
heated to 50°C for 24 hours. The product was then extracted (3x) with dichloromethane
and dried over anhydrous magnesium sulfate. After filtration the mixture was
concentrated and purified via fractional vacuum distillation yielding a viscous clear
colorless liquid. HNMR was done to verify the final product.
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THPTA synthesis:
Tripropargyl amine (1g) and 3-azido-1-propanol (3.075g) were combined in 50ml of
dried dichloromethane and the reaction vessel was purged with dry N 2.
Bistriphenylphosphine Cu(I) acetate (98.5mg) was then added using positive N 2 pressure.
The reaction was cooled in an ice bath for 4 hours. The reaction was then warmed to
room temperature and stirred for 24 hours. After the initial 28 hours the reaction was
charged with a secondary amount of both 3-azido-1-propanol (1.2g) and
bistriphenylphosphine Cu(I) acetate (98.5mg) and left to stir for another 24 hours.
Dichloromethane (50ml), H2O (50ml) and saturated EDTA solution (50ml) was added to
the reaction and then transferred to a seperatory funnel. The reaction was washed with
dichloromethane (4x) and the aqueous layer was collected and lyophilized. The product
was then dissolved in a minimal amount of 80:20 dichloromethane to methanol and
passed over activated alumina using 200 ml of the 80:20 dichloromethane to methanol as
an eluent. The colorless and clear eluent was collected, reduced in volume, poured into
300ml of diethyl ether and left to recrystallize in the freezer for 24 hours. The resulting
product was filtered and dried under vacuum. HNMR was performed to verify the
product.

Click Chemistry
PEO modified particles were suspended in DI water along with excess functional
gadolinium chelate. Copper (II) sulfate was dissolved separately in DI water with
equivalent molar amounts of THPTA ligand. The THPTA-copper sulfate solution was
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added into the particle-Gd chelate solution until the copper concentration was 2 mol
percent of the chelate. A fresh solution of sodium ascorbate was then added up to 10 mol
percent to reduce the copper to copper (I). The reactions were left to react for 8 hours.
Excess reactants and copper were removed via gel permeation chromatography and
dialysis in DI water.

Relaxivity Measurements
Relaxivity measurements were taken at 4 different firld frequencies at 37°C using
four different Bruker Minispec relaxometers fitted with a circulating water bath for
temperature control. T1 relaxation measurements were done using a typical inversion
recovery sequence, 10 data points were used to fit T1 relaxation with the largest duration
being up to 1000ms. T2 was measured using a multiecho spin echo sequence. 10 echoes
ranging from 5 ms to 500 ms were used to fit the T2 relaxation. Both T1 and T2 fitting
was done using minispec Plus software, reporting the T1 and T2 values.

Inductively Coupled Plasma Optical Emission Spectroscopy
Samples were digested initially with boiling peroxide to try and eliminate organic
from the surface. Once boiled off, concentrated nitric acid was added and boiled to
dissolve all metals from the particle complexes. Once dissolved the samples were diluted
with 2% nitric acid at a known volume. Samples were given to ChemCentre at the Curtin
University of Technology to analyze via ICP-OES.

174

Results and Discussion
Chaining Effects in Magnetic Field and Magnetite Relaxivity
Initial evaluation of the contrast agents was not for their relaxivity values, but
more to confirm their behavior in a large magnetic field. Chaining of magnetic
nanoparticles inside of a field has been observed by Saville et al. who showed that the
relaxivity decreases as a function of time as the particles assemble into linear aggregates
inside of the field.14 To examine if the PEG Fe3O4 system used for these experiments
exhibited the same behavior, the T2 values of a concentrated aqueous solution of 30nm
particles coated with a 17k Mw PEG was measured over 10 minutes inside a 60MHz
field. As can be seen in figure 6, no change in the T2 value was measured aver the course
of 10 minutes.
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Figure 6. T2 vs time curve of aqueous solution of 30nm Fe3O4 coated with 17k Mw PEO
at a concentration of ~1.5mg Fe/ml. T2 measurements were run at a field strength of
60MHz.

It can only be said however that we are in some state of equilibrium as the sample
Temperature had to equilibrate within the field for up to 2 minutes. During this time any
sort of chain assembly may have happened. It is important however that we did not see
any change in the T2 signal after temperature equilibration, as the samples relaxivity
values after equilibration do not depend on time. This allows for comparison of the
relaxivity values without influence from large mesoscale assembly.
Although initial experiments into the stability of the particles showed that chain
formation may be minimal, measured R2 values for the magnetite particles in water
showed that chain formation/mesoscale assembly was probable within the equilibration
period. Figure 7 shows the R2 values for different core size magnetite particles modified
with varying molecular weight PEO brushes at different field strengths.
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Figure 7. R2 values of PEO stabilized magnetite nanoparticles at multiple field strengths.
Relaxivity goes down as particle size increases and/or stabilizer molecular weight
decreases. Red = 15nm, Green = 20nm, Black = 25nm, Yellow = 30nm.

As both the molecular weight of the spacer and the core size go up, the relaxivity
values decrease. Initially this is counterintuitive as the larger particles should have a
much larger magnetic inhomogeneity effect, however again the results are supportive of
those reported by Saville et al. the organization of particles into larger structures
negatively impacts the R2 values. This is in line with the observations seen here as
smaller particles with larger brushes are the least prone to in field organization as the
moments are much smaller and the steric stabilization may be able to overcome the self-
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assembly forces. Any chaining or mesoscale organization process may happen at
relatively short time scales, and although unavoidable, it is important to let come to some
equilibrium state before evaluating particle based contrast agents as quick measurements
may skew the relaxivity values.
Unlike the R2 which is affected by the core size and PEO spacer due to chaining
phenomena, the R1 of the magnetite samples does not seem to follow any such trend. As
was expected, the R1 of the magnetite samples is drastically lowered at higher fields.
This is one of the reasons that particles (especially of this size), cannot be used at T1
contrast agents in general. Typical MRIs operate at between 40 and 130 MHz, at these
operational fields the R1 is drastically lowered. Combining this with a relatively stable or
increasing R2 as the field increases, the R2/R1 ratio increases dramatically making any
sort of dual mode imaging with purely magnetite particles impossible. This change in the
R1 vs. field can be seen in figure 8.
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Figure 8. R1 values of PEO stabilized magnetite nanoparticles at multiple field strengths.
R1 relaxivity drastically decreases as the field increases. Thisis problematic for dual
mode imaging as it increases the R2/R1 ratio.

Although there is an obvious field dependence of R1, there is no trend relating to the
particle size or PEO spacer on the R1 behavior of the pure magnetite particles.

Coupled Gadolinium and Magnetite
A lot of research has gone into the synthesis of functional gadolinium chelates so
they can be further modified with other moieties including polymers, small molecules,
etc. There are specifically two different routes of synthesis that have been used to make
chelate molecules for this research as is illustrated in figure 9.
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Figure 9. Two separate routes to prepare monofunctional gadolinium DO3A chelate.

Rout 1 is significantly more difficult as there are large gradient flash columns that
need to run on the compound to separate out any of the di, tri, or tetra alkylated
compounds. Synthesis rout 1 does have its advantages relating to the ability to get the
multi alkylated complexes if it was wanted to use as a step growth monomer or to build
larger macroscale complexes off of the chelators. Reaction 2 shown in figure 2 is much
easier to purify so larger quantities can be obtained quickly. However multi-functional
chelates cannot be prepared this way as it is the trialkylated complexes that salt out of
solution, which still leaves a separations issue.
To affect the R1 properties of the particles, gadolinium chelates, prepared via rout
1, were “clicked” onto the end of the stabilizing ligand. This allows for the surrounding
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water protons to easily interact with the gadolinium which will generate a measurable
enhancement in R1. Table 1 shows the change in the relaxivity values for the particle
after coupling with the gadolinium chelate. The table is only showing the 60 MHz field
strength however the trends seen are similar at all field strengths. The percent relaxivity
change is highlighted in yellow.

Table 1. Relaxivity values at 60MHz before and after Gd is added to the system.
*60 MHz No Gd With Gd % change No Gd With Gd

% change

Units in
(mM-1s-1) R1

R1

R1

R2

R2

R2

17k 15nm 3.73

9.48

154.1555

282.34

217.3

-23.0361

17k 20nm 3.834

--

--

191.85

--

--

17k 25nm 5.739

6.87

19.70727

193.97

197.9

2.026087

17 30nm

3.382

5.19

53.45949

215.52

211.78

-1.73534

7k 15nm

2.6303

4.48

70.32278

209.43

157.3

-24.8914

7k 20nm

2.4888

3.86

55.09482

183.73

153.8

-16.2902

7k 25nm

2.277

--

--

181.47

--

--

7k 30nm

1.586

--

--

127.03

--

--

5.5k 15nm 2.81

3.89

38.43416

214.3

155

-27.6715

5.5k 25nm 3.143

2.43

-22.6853

156.96

88.8

-43.4251
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It is interesting to note that with most of the samples, there was a positive change
in the R1 relaxivity which was expected due to the presence of gadolinium in the system.
What was not expected was the negative impact on the R2 signal. This negative change
actually works in favor for creating a dual mode agent as the R2 signal of magnetic
nanoparticles are high enough that lowing the R2 is a viable option to change the
relaxivity ration. In this case the gadolinium coupling works two fold by lowering the R2
and increasing the R1. The normalization process for complex systems such as these can
be difficult.
In this case it is important to note that the relaxivity values reported for the
coupled magnetite-gadolinium was obtained by normalizing to all of the magnetic
content. These values would be much higher if per mM of particles was used versus total
amount of magnetic material. The decrease in the R2 signal may be due to the fact that
the gadolinium contribution compared to the magnetite is very small, and therefore by
increasing the normalization concentration we are lowering the R2. It is also important to
note that the amount of gadolinium bound to the surface of each particle was not highly
controlled so trends are most important not necessarily the individual numbers as they
may vary depending on the gadolinium loading.
The R1 of the gadolinium loaded magnetite particles shows an interesting trend in
that the relaxivity magnitude is dependent on both the core size and the PEO spacer. This
shows that the contribution to the relaxivity of the gadolinium is not simple as the local
field from the magnetic particle influences the behavior of the gadolinium. This trend is
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illustrated in figure 10 where we see the smallest particle of 15nm with the largest PEO
spacer of 17k Mw has the largest R1 relaxivity.

Figure 10. R1 values after particles have been functionalized with Gd chelates. Trend
shows that smaller particles with larger spacers tend to see the largest R1 gains.

As the particle core size gets larger the R1 relaxivity drops. This is akin to
increasing the local field influence on the gadolinium chelate. The same behavior is seen
as the PEO spacer decreases in molecular weight, which again is akin relates to the local
field that interacts with the gadolinium. This phenomena was recently looked at by Choi
et al. who use the influence of the magnetic particle on the gadolinium complex as a
molecular ruller.15 Only a small discussion on the mechanism behind this phenomena is
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discussed, but the theory is that the electron spin fluctuation of the gadolinium chelate is
slowed via interaction with the magnetic particle. This slowing of the electron spin
fluctuation lowers the probability that electron-nuclear spin coupling occurs and therefore
reduces the R1 signal when the gadolinium is close to the magnetic particle. 15 The use as
a magnetic alternative to FRET is definitely exciting, however this also can be used as a
guideline to increase the total R1 relaxivity of the complexes. By increasing the
molecular weight and therefore the distance of the paramagnetic chelate from the particle,
the R1 signal should heavily increase. What is still unknown is how larger distances fully
effect the coupling and where the optimal threshold is for increasing the R1.
Also promising is that the lowering of the R2/R1 ratio seems to be field
dependent, in that as the field increases we see larger changes towards a more reasonable
ratio. This is illustrated in figure 11 where the relaxivity ratio at larger fields is more
drastically effected than at lower fields.
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Figure 11. Calculated R2/R1 ratios of the particles pre Gd functionalization (circles),
and post Gd functionalization (triangles). Magnitude of change between fields is altered
when Gd is present.
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That there seems to be a larger effect at larger fields is promising for possible use as a
dual T1 and T2 contrast agent as most MRI scanners operate at or above 1T. The
lowering of the ratio also seems dependent on the PEO spacer. Where the longer the
spacer the larger the change in the ratio. This s explained by the larger change in T1 due
to less interaction from the magnetite particle on the gadolinium. The ratios from the
measured samples were still a bit large to be truly useful for dual mode imaging.
However the trends seen illustrate that the use of a small particle to reduce the T2, and a
large spacer coupled with gadolinium would further reduce the ratio into the regime that
dual mode imaging would be possible, as well as maintain relatively high relaxivity
values for both modalities.

Conclusions
Gadolinium functionalized magnetic nanoparticles of varying molecular weight
and PEG spacer length were successfully synthesized. Complexes showed stable
relaxivity reading in field which suggests that any mesoscale ordering has already
occurred and is not influencing the measurements as a function of time. It was apparent
that ordering was occurring as the smaller magnetite core size showed a larger relaxivity
than the larger core samples. This is counterintuitive to theory, but is explained by
mesoscale chaining which effects the relaxivity in a negative manor. As was expected T1
behavior was only influenced by field for pure magnetite. The T1 behavior of the
gadolinium functionalized magnetite was much more complex. Trends follow that the
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larger the core and the closer the gadolinium was to the core, the lesser the enhancement
in T1 from the gadolinium. This implies magnetic interaction with the electronic spin of
the gadolinium which influences the relaxation rate of the water. Because this phenomena
is both core size and spacer length specific, it may be employed to possibly create
functional contrast agents where the intermolecular spacing between the gadolinium
pendent group and the magnetite core change as a function of environment and therefore
a shift in the T1 will be see. Moreover as the particle size decreases and the PEG tether
molecular weight increases, a lowering relaxivity ratio is seen both due to a lowering of
apparent T2 and an increase in the T1. This is promising as a sufficiently small particle
with a sufficiently spaced gadolinium chelate connected may reduce the ratio enough so
dual mode T1-T2 imaging is possible.
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CHAPTER SIX
OPTIMIZATION OF ROTATIONAL COORELATION TIMES OF T1 CONTRAST
AGENTS VIA POLY(ETHYLENE GLYCOL) CONJUGTION
Introduction
Magnetic resonance imaging (MRI) is a critical aspect of modern medicinal
practices, providing a noninvasive method to view the structure of the human body. In
addition to being noninvasive, MRI does not use ionizing radiation and provides drastic
contrast between different kinds of tissues, making it ideal in the fields of neurology,
cardiology, and oncology, among others.1 To increase the utility of MR imaging, contrast
agents (CAs) are used to further enhance the visual differences between tissues, as well
as highlight blood flow and determine organ health. It is currently estimated that one in
three MRI scans are contrast enhanced.2
The vast majority of Food and Drug Administration (FDA) approved CAs in
clinical use are gadolinium-based chelates. Gd contrast agents are administered
intravenously, and are detected indirectly via their effects on the relaxation time constants
(T1, T2, and T2*) of water in body tissues.3 By depressing the relaxation time, the CAs
alter the signal intensity in the tissue regions they occupy, thus changing the contrast
between affected and unaffected regions. This phenomenon is vital for many conditions
as relaxation signals between healthy tissues and a malignancy may be similar resulting
in minimal contrast difference in the final image. The agents also improve the visibility
of inflammation, blood vessels, and tumors that would be otherwise difficult to see.
Despite their widespread use, gadolinium-based CAs have been linked to the causation of
nephrogenic systemic fibrosis (NSF).4, 5 NSF is a disorder that is observed in patients
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with renal failure and that manifests primarily in the hardening of the skin, but can affect
virtually all body tissue and can cause severe handicaps and/or death. 6, 7 The link between
Gd-CAs and NSF was first reported in 2006, when five of nine patients in a study
developed NSF within a month of undergoing an MR angiography that utilized GdDTPA, until then the most commonly used contrast agent containing gadolinium. 8 To
date, the majority of NSF cases have been linked to gadodiamide, which is one of the
least stable gadolinium chelates available as a contrast agent. 9 As a result, chelate
stability has been linked to the cause of NSF, as unstable chelates are more likely to leach
or become unstable, thus releasing toxic Gd3+ or causing sequestration.10
The toxicity concerns Gd chelates present have forced much development in the field
tobe focused on searching for low toxicity CAs.
Of particular interest in this respect are Gd chelates conjugated with
macromolecules, which exhibit increased contrast efficiency, thus lowering the amount of
chelate (and consequently, gadolinium) required for optimal results. 1 The increased
contrast efficiency that macromolecular CAs exhibit is due to their increased relaxivity
that results from their larger molecular tumbling rate. The Solomon-BloembergenMorgan (SBM) theory of relaxation predicts that for every substance there is an ideal
tumbling rate that produces the maximum relaxivity. 11 Although not eliminating
gadolinium entirely, if the contrast agents used in scans were specifically tailored for the
scanner field strength, a lesser dose of the toxic agent would be required for the same
enhancement in contrast. By conjugating different molecular weight poly(ethylene oxide)
macromolecules onto the gadolinium chelates we can elucidate an optimal molecular
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weight for a specific field. This is then compared to diffusion coefficients of the
Poly(ethylene glycol) (PEG) itself in water to create a way to predict the optimal
molecular weight for enhancement through NMR diffusion measurements. This would
allow for all types of macromolecular contrast agents to be evaluated through diffusion
measurements, and aid in the optimization of the rotational correlation frequency.

Experimental
End group modification of polymer
PEG polymers either monomethyl ether or diol terminated of varying molecular
weights were obtained from Sigma Aldrich and were used without further purification.
The polymers were dissolved in tetrahydrofuran and the alcohol end groups were
deprotonated via sodium hydride and then reacted with propargyl bromide to yield alkyne
functionality. The polymers were then precipitated with diethyl ether and dried in a
vacuum oven to remove residual solvent. NMR was run to confirm the presence of an
alkyne end group.

Synthesis of gadolinium chelate
Cyclen and a 3x excess of sodium acetate was suspended in N,Ndimethylacetamide at -20 °C. To this a 3.2X excess of tertbutyl bromoacetate was added
drop wise over the course of 30 minutes. The reaction was allowed to come to room
temperature and react for 24 hours. After the 24 hours the reaction was poured into water
and stirred until clear. To the solution potassium bicarbonate was added until pDO3A
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(protected DO3A) precipitated as a hydrogen bromide salt. The precipitate was filtered
out, dissolved in chloroform washed with water, dried (via magnesium sulfate), and
filtered once again. The chloroform volume was reduced and the purified pDO3A HBr
salt was precipitated from diethyl ether. This was dried under vacuum to remove residual
solvent.
The pDO3A was dissolved in water at 70°C then the temperature was reduced to
40°C. a 10% KOH solution was added and after 15 minutes the freebase DO3A was
extracted 3x with hexanes which were combined and evaporated to yield a colorless
viscous oil. This was precipitated in ether to yield a white powder. NMR was done to
confirm the pDO3A compound.
pDO3A was dissolved in chloroform and was reacted with a 1.1 excess of
Mesylated azido ethanol at 40 °C for 8 hours. Mesylated azidoethanol was prepared using
the same procedure described in chapter 5. The alkylated product was concentrated and
left under vacuum to yield a yellow viscous oil which was then suspended in a 1:1
mixture of dichloromethane and triflouroacetic acid for deprotection for 8 hours, and then
evaporated to an oil. HNMR showed the disappearance of the protecting tertbutyl groups.
After deprotection the chelate molecule was stirred with equal amounts gadolinium
chloride in methanol for 6 hours. The chelated gadolinium complex was precipitated in
diethyl ether and then used with the alkyne terminal polymers for the click chemistry
reactions.
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T1 mapping of samples
All T1 and T2 mapping will be performed on a Siemens 3T Prisma clinical MRI
using the Siemens built in T1 and T2 mapping protocols with the following parameters.
T1-mapping: IR based with 250ms and 1200ms IR times. T2-mapping: multi echo, 32
echos from 30 to 960 ms. Both 3mm slices with in-plane resolution of 0.7 mm.
Approximate protocol time 30 min including a high resolution T1 weighted MPRAGE
scan (0.4 x 0.4 x 1 mm).
The Siemens protocols were validated for relaxation rate and relaxivity mapping
using a MnCl2 serial dilution calibration phantom. Relaxivity of the samples was
determined in vitro using a 2:1 serial dilution of the agent with 8 dilutions.

ICP-OES of chelate-polymer solutions
ICP-OES was run on a Perkin Elmer Optima 3100 ICP-OES running WinLab32
version 3.1 analysis software. Known masses of gadolinium conjugated polymer samples
were digested initially with <70% nitric acid. The nitric acid was boiled off and the
resulting gadolinium nitrate salts were dissolved in a known mass of 2% nitric acid
solution and run against standard solutions of gadolinium.

Diffusion NMR measurements
Diffusion measurements were done using a Bruker 300 MHz Nuclear Magnetic
Resonance (NMR) instrument. Samples of different molecular weight polyethylene
glycol in deuterium oxide were made in order to keep concentration consistent with
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relaxation measurements. Approximately 0.5 mL of the sample was transferred into an
NMR tube and inserted into the instrument. The sample was first run at 25 °C for 16
scans using the 1H NMR pulse program. The program was then changed to the diffusion
measurement program, and the gradient length (p30) and diffusion time (d20) were
optimized for each polymer. To do so, 16 scans were first run at p30=5000 μs and
d20=0.1 s, both at a 2% and 95% gradient. The ideal peak height at g=95 is 10 ± 5% of
the peak height at g=2. Once the diffusion parameters were optimized to achieve this
ratio, additional NMR spectra were collected at gradients of 5%, 12%, 25%, 37%, 50%,
62%, and 87%. The diffusion coefficient was found from the slope of the decay curve
after it was plotted using equation 1, which is analogous to the Stokes-Einstein equation.

∆

Eq. 1

Where I is the observed intensity, I0 is the reference intensity, D is the diffusion
coefficient, γ is the gyromagnetic ratio, g is the gradient strength, δ is the length of the
gradient, and Δ is the diffusion time.

Results and Discussion
Initially measurements on a simple chelate and a large multi-chelate
macromolecule were made in conjunction with relaxivity measurements made on the
gadolinium coated nanoparticles. The structures of the simple chelate and the large
macromolecular structure can be seen in figure 1.
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Figure 1. Structures of simple gadolinium chelate (A) and multi-gadolinium chelate (B)
used for initial relaxivity experiments.
The most obvious difference between the two is the size/molecular weight. This
plays a large role in the actual contrast mechanism as it influences the rotational
correlation frequency. Another major difference due to the large covalently bound
polymers will be the water binding kinetics. Due to possible steric hindrance water
binding may be suboptimal. The last major difference between the two molecules is the
number of gadolinium ions per molecule. In the case of the macromolecular complex
there were approximately 5-7 gadoliniums per molecule versus only a single in the
normal chelate. All of these factors have a large effect on the relaxivity of the contrast
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agent in question. Figure 2 shows both the chelate (Figure 1A) and the large
macromolecule (figure 1B), and their R1 and R2 relaxivities as a function of field
strength.

Figure 2. R1 and R2 relaxivity of both the simple gadolinium chelate (red) and multigadolinium complex (blue) as a function of field strength. Structures are shown in fig.1.

The major difference between the two agents is the magnitude of the relaxivities
for both R1 and R2. The increase in R1 can be attributed to multiple gadolinium water
binding sites per molecule, as well as the slowing of the molecular rotational frequency to
better match that of the Larmor frequency of the proton. The R2 difference may be that
the large amount of gadolinium occupying a small space creates large field
inhomogeneity as a magnetic particle would. Another difference is the behavior as a
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function of field. In R1 this is another manifestation of the molecular rotational
correlation. Where there exists a Larmor frequency that matches with the rotational
correlation and both above and below that frequency we expect a loss of signal. This
phenomena is predicted by the Solomon-Bloembergen-Morgan (SBM) theory of
relaxation which is illustrated in figure 3B.
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Figure 3. A) Phenomena that effect the relaxivity of paramagnetic chelates which can be
tuned to alter relaxivity values. B) Graphic illustration of SBM theory for how tumbling
rate effects relaxation times. A lower T value is desired. Figure 3A was taken from
Michael A Bruckman et al., Engineering Gd-loaded nanoparticles to enhance MRI
sensitivity via T 1 shortening, Nanotechnology, 24, 46, 2013, and reprinted with
permissions from IOP Publishing. Figure 3B was reprinted courtesy of Allen D. Elster,
MRIquestions.com.

Essentially SBM theory shows that there is a specific tumbling frequency where
the relaxation time of water protons is maximized. This maximization yields the highest
signal per gadolinium so it is of interest to optimize the tumbling rate. It is of note that
since the optimal tumbling rate is correlated to the Larmor frequency, each field strength
MRI should have a different optimal tumbling rate which can be controlled by the
coupling of macromolecules of different sizes. Complexes are illustrated in figure 4.
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Figure 4. Structure of gadolinium chelates coupled to varying molecular weight PEGs,
which were used for relaxivity measurements.

To identify the optimal molecular weight for a 3T MRI a clickable gadolinium
chelate was reacted with PEGs of varying molecular weights and their relaxivity
measured. The relaxivity of these compounds is shown in figure 5. As the molecular
weight increases the tumbling rate of the molecule is decreased and the relaxivity
increases until tumbling slows beyond the Larmor frequency in which case relaxivity
begins to decrease. The relaxivity of the molecular weight specific chelates is shown in
figure 5.
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Figure 5. Relaxivity vs molecular weight of the varying chelate molecules. Red points
denote bifunctional complexes which seemed to have no marked effect on the relaxivity
trend.

After an initial drop in the relaxivity was seen with total molecular weights of
approximately 1500 g/mol. This may be in part due to restriction of water moleculegadolinium interaction which would slow the water exchange rate and lower the apparent
relaxivity of the complex. However, after an initial drop in the relaxivity there is an
increase until a peak relaxivity at approximately 5,000 g/mol comparable to the chelate
itself and then another drop off in relaxivity. It is important to note that the drop off is not
near the same rate of increase at low molecular weights as the x-axis in figure 2 is
logarithmic. This is interesting as it is better to be on the larger side of optimal molecular
weight than the smaller as the decrease is much less severe. It is also interesting to note
that the optimal molecular weight in this case is close to the critical entanglement weight
of PEG of approximately 4000 g/mol. This may play a role in the sudden downturn in the
per gadolinium relaxivity as further steric interactions may be influencing the water
binding, exchange, or rotational frequency all of which influence the overall relaxation.
Although the relaxivity values for the PEG conjugated chelates are, at their best,
similar to that of clinically used gadolinium chelates, the trend seen can be used to
optimize other more promising macromolecular chelates by looking at the diffusion
coefficients of the macromolecules and comparing them to the relaxivity measured.
Diffusion measurements of different molecular weight PEGs are shown in figure 6.
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Figure 6. Diffusion coefficients of varying molecular weight PEGs measured via diffusion
NMR. Change in diffusion coefficient slows as molecular weight increases.

Although diffusion is not a direct measurement of the rotational correlation
frequency, the translational diffusion is similar to rotational diffusion as both derive from
Einstein equations where particle radius and viscosity are important in determining the
diffusion coefficients for both kinetic and rotational diffusion. As the molecular weight of
the polymer increases the diffusivity (diffusion coefficient) decreases significantly
initially but begins to level out at higher molecular weights. This is interesting as the rate

203

of change in the diffusivity as a function of molecular weight matches well with rate in
change in the relaxivity. The diffusivity vs relaxivity graph which would amount to the
diagnostic tool for macromolecular contrast agents is shown in figure 7.

Figure 7. Generated “standard curve” showing the measured relaxivity as a function of
measured diffusion coefficient.

The slowed change in the diffusion coefficient at high molecular weights explains
why over large changes in molecular weight after the peak relaxivity relatively small
changes in the relaxivity are seen. It follows that if the change in the rotational correlation
is relative to the change in translational diffusion, then at higher molecular weights the
rotational component would also begin to slow in its variance with molecular weight
leading to relaxivity closer to the optimal. Although not the sole reason for the enhanced
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relaxivity values seen for macromolecular chelates in literature, this phenomena may play
a part as it is beneficial to be on the larger side of optimal as the diffusion is slow to
deviate from the optimal.
It may be possible to use this phenomenon to maximize the relaxivity of other
macromolecular chelates. If the diffusion coefficient can be measured of the molecule in
question it can be matched to the corresponding relaxivity value, which would be able to
direct the synthesis procedure to make the complex larger or smaller. It would also be
feasible to generate similar curves for other commonly used field strengths. This, in
theory, would influence the optimal diffusion coefficient as if the field is lower the
Larmor frequency would also be lower and therefore a slower rotation would be optimal
and visa-versa with a larger field strength. When looking at the diffusion coefficient as a
guideline for molecular weight it is very important to note that the rotational frequency is
only one of many factors that influence the relaxivity and more research needs to be done
to elucidate a set of rules and guidelines for synthesizing optimal paramagnetic
macromolecular contrast agents.

Conclusion
This work establishes a simple method to evaluate and optimize the rotational
frequency of novel contrast agents using diffusion behavior of PEG as a guide for optimal
relaxivity enhancement. PEGs of varying molecular weights were successfully attached
to gadolinium chelates via a robust click chemistry reaction. Initial hypothesis was that a
marked improvement as tumbling slowed would be seen, however the macromolecules
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had a negative effect on water shell kinetics and dynamics possibly due to steric
hindrance or solvation. Although this was the case a clear trend of molecular weight vs.
relaxivity was seen and was in agreement with the Solomon-Bloembergen-Morgan theory
of relaxation with the only major difference being a much smaller change in relaxivity as
the molecular weight increased above the optimal. Diffusion measurements of the PEG
macromolecules were also done, and their behavior correlated with the observed changes
in relaxivity. This diffusivity vs. relaxivity can be used as a tool to evaluate novel
macromolecular contrast agents, and can be optimize for their rotational behavior to
match a 3T magnet. This method could also be done for other magnetic field strength
which ideally would lead to the development of field specific contrast agents, instead of
the one size fits all approach we currently have in the medical imaging field today.
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CHAPTER SEVEN
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK
The subject of magnetic nanomaterials, their synthesis, modification, and
ultimately application still has an extremely large amount of undiscovered opportunity.
Even today many of the “simple” subjects on the most basic of magnetic materials are
changing in ways that will cascade through to the final applications based research that
many scientists currently take part in. In this chapter I will discuss broad the broad
conclusions of my research, future applications, as well as areas that may need focus,
from a materials science perspective starting from the nanomaterials synthesis through
the final application of these novel materials.

Synthesis
One of the most difficult problems in synthesis of nanomaterials to solve is not
necessarily creating the material, but being able to create the material reproducibly. Many
of these novel particles rely on properties that may deviate greatly if the particles in
question are a few nanometers different in size or composition. This is especially true
when talking about magnetic nanomaterials. Because two of the major defining traits of
magnetic particles (relaxation time and magnetocrystalline anisotropy) are so heavily
reliant on the size, shape, and composition of the particles. It is not just imperative that
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there is a synthesis, but that the synthesis is reproducible in a way that the particles can be
“manufactured” in high enough quantities so they can be further used for downstream
engineering problems. As of right now, scale up of highly monodisperse, highly
crystalline magnetic nanoparticles is difficult. Fluctuation in temperatures within large
reaction vessels has proven to affect the morphology of the particles yielding faceted
nanocrystals looking more like pebbles than spheres. These issues are pervasive in the
nanoparticle community, and it is one of the reasons that the extended LaMer synthesis is
so valuable. The reproducibility of the synthesis is very high for magnetite, and drips
could be run continuously as to have mass production in a small scale reactor, but it is
important to evaluate the synthesis procedure when transitioning to other more complex
materials such as nonstoichiometric ferrites.
As was seen in chapter 2 the transition to a mixed ferrite material such as
manganese ferrite, nickel ferrite, or zinc ferrite using a simple one pot synthesis was not a
simple follow the magnetite procedure. Different sizes, and morphologies were obtained
using the same synthetic procedure. This is not to say that this will not work with minor
alterations, or with a chosen material just that it is important to thoroughly investigate the
effect of a certain synthesis procedure on the resulting material.
Another promising line of research that may be undervalued in the nanosynthesis
community is the use of simulation to help narrow materials space. If the idea is to
synthesize materials that are useful for engineering purposes, optimization of the ideal
parameters is crucial. Using conventional wet methods it is difficult to predict or even
identify the effect of doping on the materials properties. This was seen with the cobalt
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ferrite where the AC magnetometry peak loss frequency was maximized at a
nonstoichiometric value. Without completely characterizing a large set of reactions this
behavior would not be seen. This is even more complicated when multiple dopant
elements are introduced into the system as the materials space grows exponentially.
Using simulation, it may be possible to narrow down to a subset of “interesting”
materials which would both guide and accelerate materials discover and lead to the next
generation of complex nanomaterials.

Functionalization
When talking about functionalization, one of the most overlooked subjects is the
actual ligand exchange or initial surface chemistry. Understandably, it is not an illustrious
topic, as it is an intermediate enroute to any final product. It seems that in the magnetic
nanoparticle community, everyone wants to have a nanoparticle with low size
distribution, high crystallinity, etc. but they want it in an aqueous environment. Typically,
these desirable characteristics are produced via the thermal decomposition synthesis,
which is done using a hydrophobic ligand. It is only after some sort of encapsulation or
ligand exchange that the particle become dispersible in aqueous media. There are many
of these exchange procedures reported in literature, however they are difficult to repeat
and often afford low yields. This is a highly pertinent issue that needs to be addressed as
any sort of scale up requires multiple batches each with a yield of 2% or lower. This is
not sustainable in the long run for any sort of biomedical application.
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Disregarding the issues of ligand exchange, the possibilities of functionalization
are almost endless when it comes to functionalization with biomolecules or other
secondary functional moieties. Considering this, as well as the tunability of the particles,
it is surprising that there is not more work in sensor applications. In vitro sensors are
ideal from a technology perspective as they do not need to pass heavy FDA regulations
and the working materials space is much wider as toxicity is of no concern. One could
easily imagine a “cocktail” of particles each with a unique magnetic signature coupled
with a unique biotag. This could be useful both for sensing low level metabolites, cell
sorting, disease identification, selective color imaging, etc. Here the challenge would be
the resolution of measurement. Considering the sensitivity of SQUIDs and the control
over the nanomaterials that we have today, high resolution, high sensitivity
measurements should be possible.
This does not take away from the fact that these materials are proving useful as
possible in vivo treatments. As was seen in both chapter 3 and chapter 4, the potential as
both a unique antibacterial platform, and as a targeted pharmaceutical agent is definitely
there. It is just worrisome that after 30 years on magnetic nanoparticles there has been
only one wide spread use (dextran coated, coprecipitation prepared, magnetite as a T2
contrast agent). It may be that in another 30 years we will see the in vivo use of
nanomaterial based medicine, but adoption has been slow, even for relatively benign
nanomaterials.

Application
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Magnetic materials for use in medicine still has a ways to go before mainstream
adoption. Many groups are currently working on trying to bring MagMED using
magnetic particles into the clinical space. This is especially true in Europe where
regulation is more reasonable when it comes to novel medicines. This MagMED
treatment, demonstrate in chapter 3, is typically used as a cancer treatment and this is
where almost all of the literature on MagMED is focused. There is however a lot of
potential for it to be used as an alternative antibiotic for other much more devastating
diseases as the glycan functional particles work two fold in preventing disease. Another
are that could be interesting is using the gadolinium functionalized nanoparticles as ion
sensors in MRI. Currently we are working on ion responsive gadolinium based contrast
agents to measure calcium levels in vivo. In theory one of the larger issues with these
agents will be that they are not ion specific. The gadolinium coated nanoparticles could
be ion specific. The main difference would be that instead of using PEG as the stabilizing
brush, a modified calmodulin protein could be used. In the presence of calcium 2+ the
calmodulin protein undergoes a conformational change as the calcium binds. This would
change the distance between the gadolinium on the outside of the particle and the
magnetic core which would lower the R1. This change should be measurable in vivo
using an MRI especially if optimal magnetite core and calmodulin length were used. This
could work with any externally stimuli responsive polymers including pH, temperature,
metabolite, etc.

212

Final Remarks
I do believe that magnetic materials will find adoption into clinical space. As
nanoscientists we are lucky that there has already been precedence for a magnetic
nanomaterial that has been FDA approved. I do believe that this will help bring the
forefront of this field into the public space. I also believe that we have just scratched the
surface of what these materials have to offer from a biomedical standpoint. Everything
from diagnostics and imaging to disease treatment and prevention can be addressed
through the intervention of nanomagnetics. Here is hoping that in my lifetime I get to see
the small part I played make a difference in the future of heathcare.
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